

## Functionalised Bicyclic *exo*-Glycals by Alkynol Cycloisomerisation of Hydroxy 1,3-Diynes and Hydroxy Haloalkynes

by Zhiwei Miao, Ming Xu, Barbara Hoffmann, Bruno Bernet, and Andrea Vasella\*

Laboratorium für Organische Chemie, ETH-Hönggerberg, HCI, CH-8093 Zürich

Herrn Prof. Dr. Rolf Huisgen mit den besten Wünschen herzlich zugeeignet.

Functionalised bicyclic *exo*-glycals are readily obtained by base-catalysed (typically MeONa in MeOH) alkynol cycloisomerisation of ethynylated cyclic saccharides. Thus, base treatment of the phenylethynyl- and halogenoethynylated 1-*O*-acetyl-ribofuranoses **22**–**24** and the 4-ethynylated 1-thioglucofuranosides **30**–**33** gave – after deacetylation – selectively the (*Z*)-configured exocyclic enol ethers **26**–**28** (84–91%) and **34**–**37** (63–76%), respectively, resulting from a *trans*-5-*exo-dig* cyclisation. The ring closure to the *trans*-dioxahexahydroindans **34**–**37** is favoured by a concerted intramolecular protonation of the intermediate vinyl anion by the neighbouring HO–C(3). Cycloisomerisation of the 6-*O*-acetyl-4-(phenylethynyl)-1-thio- $\alpha$ -D-glucopyranoside **39** occurred *via* the corresponding phenylethynylated allenes to provide the *galacto*-configured (*Z*)- and (*E*)-*cis*-dioxahexahydroindans **40** (30%) and **41** (51%). Surprisingly, the HO–C(4) unprotected  $\alpha$ -D-galactopyranosyl-buta-1,3-diyne **15** and the  $\beta$ -D-glucopyranosyl-buta-1,3-diyne **51** (and its 2-bromoethynyl analogue) undergo a 6-*exo-dig* ring closure to the 2,5-dioxabicyclo[2.2.2]octanes **16**–**19** and **52/53**, respectively, the ring closure requiring a boat conformation ( $B_{1,4}$  for **15**,  ${}^1,4B$  for **51**). Ring strain (*anti*-reflex effect) prevents an alkynol cycloisomerisation of 4-(phenylbuta-1,3-diyne, bromoethynyl, or iodoethynyl)levoglucosan **56**–**59**, and **56** reacted by elimination to the hex-1-ene-3,5-diyne **59** (82%), while isomerisation of **57** and **58** led to epimeric mixtures of the haloallenes **60** (82%) and **61** (68%).

**Introduction.** – *exo*-Glycals are versatile synthetic intermediates used for the preparation of, *e.g.*, ulosides [1–3], substituted *endo*-glycals, and functionalised *C*-glycosides; their chemistry has recently been summarised by *Taillefumier* and *Chapleur* [4]<sup>1)</sup>. Methods for the synthesis of *exo*-glycals comprise the *Wittig*-type olefination of glyconolactones and glycosylphosphonium salts, the methylenation of glyconolactones with *Tebbe* and *Petasis* reagent, addition–elimination reaction, reductive elimination of ketopyranosyl bromides, cyclisation of ethenylated alditols induced by electrophiles, followed by elimination, and the *Ramberg*–*Bäcklund* rearrangement of glycosyl sulfones.


While alkynol cyclisation (cycloisomerisation) has been used as early as 1959 for the structure elucidation of hydroxylated oligoacetylenes, as illustrated by the high-yielding cyclisation of **1** to **2** [9][10] (*Scheme 1*), this facile cyclisation has, surprisingly, not been used for the transformation of carbohydrates into *exo*-glycals, nor has the high yielding base- or Ag<sup>+</sup>-promoted cyclisation of hydroxylated haloalkynes and terminal alkynes, such as **3** to **4** and **5** to **6** [11–14] found such an application<sup>2)</sup>. Acceptor-

<sup>1)</sup> For more recent reports, see [5–8].

<sup>2)</sup> Alk-3-ynols and alk-4-ynols undergo a ready formal 5-*endo-dig* and 6-*endo-dig* cyclisation to *endo*-glycals *via* transition-metal (Mo, Cr, W, Ru, Pd) vinylidene intermediates (see [15–17] and [18] for a recent review). Sequential cyclisation and addition of alkynols to the resulting *endo*-glycals was used for the preparation of oligosaccharides [16][19].

substituted acetylenes cyclise under basic conditions exclusively to 2-methylideneoxolanes; a 1*H*-isochromene derivative was identified as an isomerisation product from the corresponding 1-methylidene-1,3-dihydroisobenzofuran [20][21].

Scheme 1



In the context of the synthesis of acetylenosaccharides (see, *e.g.*, [22–25] and [26] for a recent review), we investigated the alkynol cycloisomerisation of buta-1,3-diyne and haloethynylated alcohols to *exo*-glycals, and report the results of the cyclisation of glycofuranose- and glycopyranose-derived hydroxyacetylenes.

**Results and Discussion.** – To further evaluate the pronounced electrophilic properties of buta-1,3-diynes and haloalkynes, we calculated the orbital energies of acetylene (**7**), buta-1,3-diyne (**9**), the halogenated acetylenes **11–13**, HCN (**8**), and propiolonitrile (**10**) using the semi-empirical programs AM1 [27] and PM3 [28] implemented in the AMPAC 6.55 package [29]. The electrophilicity of these compounds correlates with the energy and coefficients of the LUMO (Table 1). According to both AM1 and PM3 calculations, the LUMO energies of **8–13** are more or less below the one of acetylene (**7**), except for the iodoacetylene **13**, as calculated by PM3 (similar energy). The LUMO energy of buta-1,3-diyne (**9**) is markedly lower than that of acetylene (**7**) and HCN (**8**) (AM1:  $\Delta E(\mathbf{9}/\mathbf{7}) = 1.375$ ,  $\Delta E(\mathbf{9}/\mathbf{8}) = 1.047$ ; PM3:  $\Delta E(\mathbf{9}/\mathbf{7}) = 1.286$ ,  $\Delta E(\mathbf{9}/\mathbf{8}) = 0.734$  eV), evidencing a much higher electrophilicity. The propiolonitrile (**10**) is even more electrophilic (AM1:  $\Delta E(\mathbf{10}/\mathbf{7}) = 1.809$ ,  $\Delta E(\mathbf{10}/\mathbf{8}) = 1.481$ ; PM3:  $\Delta E(\mathbf{10}/\mathbf{7}) = 1.862$ ,  $\Delta E(\mathbf{10}/\mathbf{8}) = 1.310$  eV). The LUMO energy of the halogenated acetylenes **11–13** is higher than the one of buta-1,3-diyne (**9**), suggesting a reduced electrophilicity. According to the AM1 calculation, the LUMO energy drops from chloro- to bromo- and iodoacetylene, while PM3 calculation led to an inverse sequence. This difference is probably due to the decreasing accuracy in semi-empirical calculations of atoms of the lower rows; the high LUMO energy resulting in the PM3 calculation of the iodide **13** suggests that the heavier atoms are less well implemented in PM3 than in AM1, and that iodoacetylene (**13**) and bromoacetylene (**12**) are better acceptors for nucleophiles than chloroacetylene (**11**).




Table 1. Energy and Coefficients of the LUMO of 7–13 Obtained by AM1 and PM3 Calculations

	Energy [eV]		Coefficient at							
			atom 1		atom 2		atom 3		atom 4	
	AM1	PM3	AM1	PM3	AM1	PM3	AM1	PM3	AM1	PM3
<b>7</b>	2.053	2.009	-0.71	-0.71	0.71	0.71				
<b>8</b>	1.725	1.457	-0.73	-0.72	0.69	0.69				
<b>9</b>	0.678	0.723	-0.57	-0.56	0.43	0.43	0.43	0.43	-0.57	-0.56
<b>10</b>	0.244	0.147	-0.61	-0.60	0.47	0.46	0.40	0.42	-0.49	-0.51
<b>11</b>	1.663	1.713	-0.71	-0.71	0.69	0.69	-0.15	-0.17		
<b>12</b>	1.447	1.763	-0.72	-0.72	0.68	0.69	-0.14	-0.10		
<b>13</b>	1.412	2.025	-0.72	-0.71	0.68	0.69	-0.11	-0.11		

Both AM1 and PM3 calculations result in similar coefficients for the LUMO orbitals of 7–13 (Table 1). The largest coefficient at C(1) of 9–13 predict that nucleophilic attack is favoured at the unsubstituted acetylenic C-atom.

The regioselectivity of the addition of (hard) nucleophiles to acetylenes is also influenced by the charge distribution. AM1 and PM3 calculations led to similar net atomic charges for 7–13 (Table 2). That 8–10 are more electrophilic than acetylene (7) is predicted by the lower net atomic charge on C(1) of 8–10. A higher reactivity towards hard nucleophiles of the buta-1,3-diyne (9) internal C-atoms is predicted on the basis of their lower net atomic charge. The net atomic charges of propiolonitrile (10) are in keeping with an expected attack of hard nucleophiles at the cyano C-atom. The net atomic charge of C(1) decreases in the series chloro-, bromo-, to iodoacetylene indicating the same relative reactivity as deduced from the LUMO energy values of the AM1 calculation.

Table 2. Net Atomic Charges of 7–13 Obtained by AM1 and PM3 Calculations

	Net atomic charge at							
	atom 1		atom 2		atom 3		atom 4	
	AM1	PM3	AM1	PM3	AM1	PM3	AM1	PM3
<b>7</b>	-0.22	-0.19	-0.22	-0.19				
<b>8</b>	-0.19	-0.16	-0.05	-0.07				
<b>9</b>	-0.17	-0.15	-0.06	-0.05	-0.06	-0.05	-0.17	-0.15
<b>10</b>	-0.10	-0.08	-0.10	-0.08	-0.02	0.00	-0.01	-0.04
<b>11</b>	-0.18	-0.16	-0.21	-0.32	0.16	0.28		
<b>12</b>	-0.14	-0.12	-0.32	-0.30	0.22	0.23		
<b>13</b>	-0.12	-0.14	-0.40	-0.34	0.29	0.28		

*Alkynol Cycloisomerisation of  $\alpha$ -D-Glucopyranosylbuta-1,3-diyne.* Exploratory experiments performed in 1995 to cyclise partially protected 4-buta-1,3-diynylated glucopyranosides failed. However, treatment of the  $C_2$ -symmetric di( $\alpha$ -D-glucopyranosyl)buta-1,3-diyne **15** obtained from **14** [30][31] with excess  $\text{Na}_2\text{S} \cdot 9 \text{H}_2\text{O}$  in boiling  $\text{MeOCH}_2\text{CH}_2\text{OH}$  gave the ynenol ether **16** (60%, *Entry 1* in *Table 3*), an *exo*-glycal, and not the expected thiophene (*Scheme 2*). Similarly, benzylation of **15** with NaH and BnBr in DMF at  $0^\circ$  gave a mixture of the perbenzylated *exo*-glycals **18** (53%) and **19** (21%). This result was rather surprising, considering that the alkynol cycloisomerisation of **15** requires a conformational change of the pyranosyl ring from a chair to a  $B_{1,4}$  boat. Best yields of **16** (70%) were obtained with  $\text{K}_2\text{CO}_3$  albeit in a slower reaction (24 h vs. 0.6 h; *Entry 3*); increasing the strength of the base lowered the yield of **19** (*Entries 1–3*).




Table 3. *Conditions and Yields in the Alkynol Cycloisomerisation of 15 and 16*

Entry	Starting material	Solvent	Base (8–10 equiv.) and reagent	Conditions	Products and yields
1	<b>15</b>	$\text{MeOCH}_2\text{CH}_2\text{OH}$	$\text{Na}_2\text{S} \cdot 9 \text{H}_2\text{O}$	0.6 h at reflux	60% of <b>16</b>
2	<b>15</b>	$\text{MeOCH}_2\text{CH}_2\text{OH}$	$\text{MeOCH}_2\text{CH}_2\text{ONa}$	48 h at reflux	45% of <b>16</b>
3	<b>15</b>	$\text{MeOCH}_2\text{CH}_2\text{OH}$	$\text{K}_2\text{CO}_3$	24 h at reflux	70% of <b>16</b>
4	<b>15</b>	DMF	NaH, BnBr	3 h at $0^\circ$	53% of <b>18</b> , 21% of <b>19</b>
5	<b>16</b>	$\text{MeOCH}_2\text{CH}_2\text{OH}$	$\text{Na}_2\text{S} \cdot 9 \text{H}_2\text{O}$	0.6 h at reflux	no reaction
6	<b>16</b>	$\text{MeOCH}_2\text{CH}_2\text{OH}$	$\text{MeOCH}_2\text{CH}_2\text{ONa}$	48 h at reflux	10% of <b>17</b>
7	<b>16</b>	$\text{MeOCH}_2\text{CH}_2\text{OH}$	$\text{K}_2\text{CO}_3$	24 h at reflux	37% of <b>17</b>
8	<b>16</b>	DMF	NaH	3 h at $0^\circ$	no reaction

While no product of double ring closure could be detected in the crude product of **15**, we obtained the doubly ring-closed,  $C_2$ -symmetric dienol ether **17** by subjecting the ynenol ether **16** to the same conditions as **15**, although the yields of the second cyclisation were distinctly lower (37% with  $K_2CO_3$ , 10% with  $MeOCH_2CH_2Na$ ; *Entries 7 and 6 in Table 3*).

The enol ether moiety of **16–19** is evidenced by an IR band of medium strength at  $1654–1662\text{ cm}^{-1}$ . The  $^1H$ - and  $^{13}C$ -NMR spectra of **16**, **18**, and **19** evidence an  $\alpha$ -D-glucopyranosylethynyl moiety ( $^{13}C$ -NMR: 2 *ss* at  $87.6–85.8$  and at  $84.6–83.5$  ppm for C(10) and C(9), resp., 6 BnO groups in **16**, and 7 BnO groups in **18** and **19**). HO–C(14) of **16** resonates as *d* at 2.40 ppm, and  $J(14,OH) = 1.7$  Hz evidences an intramolecular H-bond to BnO–C(13), which is corroborated by the IR band at  $3590\text{ cm}^{-1}$  (cf. [32][33]). The NMR spectra of **16** and **18** are very similar apart from the replacement of OH by OBn and reveal the same configuration. H–C(8) of **16** and **18** resonates as a *d* at  $4.64–4.66$  ppm, whereas the *d* of H–C(8) of **19** is shifted downfield to 5.15 ppm due to the neighbouring O–C(3), allowing to unambiguously assign the (*E*)-configuration to **19** and the (*Z*)-configuration to **16** and **18**. This assignment is confirmed by strong NOEs between H–C(8) and H–C(6) of **16** (8–14%). H–C(8) of **16**, **18**, and **19** couples with H–C(11) ( $J(8,11) = 1.9–2.0$  Hz), but not with H–C(6). These couplings evidence the 2,5-dioxabicyclo[2.2.2]octane skeleton of **16**, **18**, and **19** and a 6-*exo-dig* alkynol cycloisomerisation of **15**<sup>3</sup>). H–C(6) of **19** is *cis*-oriented to the ethynyl group and, therefore, resonates downfield as a broad *d* at 5.11 ppm ( $J(5,6) = 3.6$  Hz), whereas the signal of H–C(6) of **18** appears upfield at  $4.07–4.09$  ppm. Due to virtual coupling [37] (H–C(4) and H–C(5) resonate as a narrow *AB* system at  $3.91–3.88$  ppm), H–C(6) of **16** and **18** shows an additional splitting (**16**:  $J = 3.5$  and  $1.9$ , **18**:  $J = 2.0$  and  $1.4$  Hz). As it is typical for enol ethers, the *s* of C(7) appears at low field (**16/18**: 159.6, **19**: 161.8 ppm) and the *d* of C(8) at high field (**16/18**: 83.4–83.6, **19**: 85.35 ppm). The NMR spectra of **17** show a single set of signals and evidence the  $C_2$ -symmetry. H–C(8) resonates as *s* at 5.39 ppm (no allylic coupling). The upfield shift of the *d* of H–C(6) (4.14 ppm,  $J(5,6) = 3.0$  Hz) ascertains the (*Z,Z*)-configuration. The *s* of C(7) of **17** appears at 146.6 and the *d* of C(8) at 97.9 ppm.

The formation of 2,5-dioxabicyclo[2.2.2]octanes in the alkynol cycloisomerisation of **15** and **16** agrees well with the result of the semi-empirical calculation, *i.e.*, an enhanced electrophilicity at the terminal C-atoms of the buta-1,3-diyne moiety. The lower yields of **17** than of **16** (see *Table 3*) evidence the decreased electrophilicity of the alkynylated enol ether. The cycloisomerisation promoted by  $K_2CO_3$ ,  $Na_2S \cdot 9 H_2O$ , and  $MeOCH_2CH_2ONa$  led selectively to the (*Z*)-configured enol ethers **16** and **17**, whereas cyclisation of **15** promoted by NaH led to a *ca.* 7:3 mixture (*Z*)-**18**/(*E*)-**19**. NaH did not promote the cyclisation of **16** (*Entry 8 in Table 3*). That a rather weak base in a protic solvent and at higher temperature led to the best results of the cycloisomerisation suggests that a fast chair–boat interconversion, and particularly a concerted protonation of the evolving linear *trans*-vinyl anion<sup>4</sup>) are favourable. Protonation of a fully fledged vinyl anion as resulting from the NaH-promoted cyclisation results in a mixture of the (*E*)- and (*Z*)-ynenol ethers **18** and **19**.


<sup>3</sup>) A 7-*endo-dig* alkynol cycloisomerisation of **15** would lead to a 2,5-dioxabicyclo-[3.2.2]non-6-ene skeleton. One expects a vicinal coupling  $J(6,7)$  of 6.6 Hz (MM3\* modeling [34]) and the absence of a coupling between H–C(7) and H–C(11); compare with corresponding values of 8 and 9.5 Hz of a bicyclo[3.2.2]non-7-ene and a bicyclo[3.2.2]non-8-en-7-one, respectively [35][36].

<sup>4</sup>) As shown by AM1 calculations, deprotonation at C(1') of (*E*)- and (*Z*)-6-(but-2-ynylidene)-2,5-dioxabicyclo[2.2.2]octane leads to the same almost linear (*Z*)-vinyl anion ( $C=C^-$ –C bond angle =  $163^\circ$ , O–C=C<sup>–</sup>–C dihedral angle =  $-0.2^\circ$ ), whereas deprotonation of 6-methylidene-2,5-dioxabicyclo[2.2.2]octane gives two trihedral anions ( $C=C^-$ –H bond angles =  $122–125^\circ$ ). The (*E*) anion is favoured by an anomeric effect. Treatment of 2-(but-2-ynyl)phenol with aqueous NaOH led indeed selectively to the (*Z*)-configured enol ether [38].

The successful alkynol cycloisomerisation of **15** prompted us to further investigate such cyclisations of monosaccharides.

*Alkynol Cycloisomerisation of D-ribo-Hex-5-ynofuranoses.* The alkyne **20** was prepared from D-ribose (22% overall yield) via a *Corey–Fuchs* reaction [39]. Acetylation of **20** (AcOH, Ac<sub>2</sub>O, and conc. H<sub>2</sub>SO<sub>4</sub>) in THF at room temperature gave 81% of the β-D-configured acetate **21**<sup>5)</sup> (Scheme 3). *Sonogashira* coupling between **21** and PhC≡CBr yielded 81% of the butadiyne **22**. Treatment of **21** with NBS and catalytic amounts of AgNO<sub>3</sub> [41] or with *N*-iodosuccinimide (NIS) and 1.5 equiv. of AgNO<sub>3</sub> [41][42] gave the bromide **23** (95%) and the iodide **24** (80%), respectively. Chlorination of **21** with *N*-chlorosuccinimide (NCS) was sluggish. Treatment of **21** with 5.25% aqueous NaOCl [42] led to complete chlorination, but also cleaved the anomeric AcO group. The intermediate hemiacetal cyclised *in situ* to the chloro-enol ether **25** (90%). Deacetylation of **22–24** with MeONa in MeOH was accompanied by cyclisation to the *exo*-glycols **26** (91%), **27** (84%), and **28** (91%), respectively. The cyclisation of the halides **23** and **24** occurred at room temperature (overnight) and that of the butadiyne **22** at 78° (4 h).

Scheme 3



a) Ac<sub>2</sub>O, conc. H<sub>2</sub>SO<sub>4</sub>, AcOH/THF 1:1; 81%. b) (Bromoethynyl)benzene, [Pd<sub>2</sub>(dba)<sub>3</sub>], CuI, P(fur)<sub>3</sub>, Et<sub>3</sub>N, DMF; 81% of **22**. c) NBS, AgNO<sub>3</sub>, acetone; 95% of **23**. d) NIS, AgNO<sub>3</sub>, NH<sub>3</sub>/H<sub>2</sub>O, acetone; 80% of **24**. e) NaOCl, H<sub>2</sub>O; 90%. f) MeONa, MeOH; 91% of **26**; 84% of **27**; 91% of **28**.

The *ribo*-hexofuranosides **21–28** show couplings of *ca.* 0 Hz for *J*(1,2) and *J*(3,4) (Table 4 in the *Exper. Part*). This evidences an *E<sub>O</sub>* conformation also for the acetates **21–24** where the C(1) and C(4) substituents are pseudoaxial. The enol–ether moiety of **26–28** is evidenced by an IR band at 1692–1674 cm<sup>-1</sup>. The *s* of the

<sup>5)</sup> For the use of an anomeric mixture containing **21**, see [40].

olefinic H–C(6) resonates at 4.94 (**26**) and 5.82–5.83 ppm (**25**, **27**, and **28**). The absence of coupling between H–C(6) and H–C(4) agrees with a 3-methylidene-2,7-dioxabicyclo[2.2.1]heptane but not with a 2,8-dioxabicyclo[3.2.1]oct-3-ene skeleton, where a vicinal coupling of *ca.* 6 Hz between the olefinic and bridgehead H is expected. H–C(4) of **25**–**28** resonates at 4.93–4.95 ppm at a similar position as H–C(4) of **21**–**24** (4.87–4.97 ppm); the absence of a downfield shift evidences the (*Z*)-configuration. The *s* of C(5) appears at 155.2 (**26**), 153.0 (**28**), 148.7 (**27**), and 146.8 ppm (**25**). As expected, C(6) resonates as a *d* at high field and the chemical shift is strongly influenced by the substituent (88.6 ppm for the chloride **25**, 80.1 ppm for the acetylene **26**, 74.5 ppm for the bromide **27**, and 41.6 ppm for the iodide **28**). The signals for the C≡C group of **26** were assigned according to [43], C(7) resonating at 82.61 and C(8) at 92.43 ppm.

The (*Z*)-configuration of **25**–**28** (dihedral angle O–C(5)–C(6)–X (X = C(7) or halogen)  $\leq \pm 1.0^\circ$ ) was established by X-ray crystal-structure analysis. The unit cell of **26**–**28** contains a single molecule, whereas the unit cell of the chloride **25** contains two slightly different molecules (*Fig. 1*)<sup>6</sup>. The analysis shows typical bond lengths and bond angles, such as C(1)–OC(5) of 1.453–1.472 Å, C(5)–O of 1.366–1.397 Å, C(5)=C(6) of 1.307–1.328 Å, O–C(5)=C(6) of 124.1–125.9°, and C(5)–C(6)–X (X = C(7) or halogen) of 122.3–127.8°. The C–Hal bond lengths are 1.735 and 1.741 Å (chloride **25**), 1.869 Å (bromide **27**), and 2.063 Å (iodide **28**). The C≡C bond length of **26** is 1.199 Å, and a slight deviation of the acetylene group from linearity is indicated by the bond angles C(6)–C(7)≡C(8) of 172.3° and C(7)≡C(8)–C(1') of 176.8°. The  $\pi$ -planes of the enol-ether moiety and the Ph group of **26** are orthogonal.





Fig. 1. Crystal structure of the 1-5-anhydro-D-ribo-hex-5-enofuranoses **25**–**28**

<sup>6</sup>) The crystallographic data have been deposited with the *Cambridge Crystallographic Data Centre* as deposition No. CCDC-248024 (**26**), CCDC-248027 (**27**), CCDC-248026 (**28**), CCDC-248025 (**25**), CCDC-248028 (**57**), and CCDC-248029 (**59**). Copies of the data can be obtained, free of charge, on application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax. +44(1223)33 6033; e-mail: deposit@ccdc.cam.ac.uk).

The exclusive formation of **25–28** shows that a 5-*exo-dig* alkynol cycloisomerisation of D-ribo-hex-5-ynofuranoses is favoured, probably by proximity of the reacting centers, although a 6-*endo-dig* cyclisation does not suffer from additional steric strain. However, a 5-*exo-dig* alkynol cycloisomerisation of C(6)O unprotected 4-ethynylglucopyranosides leading to *trans*-dioxahexahydroindans is sterically disfavoured. We wondered whether such glucopyranosides would undergo a 6-*endo-dig* cyclisation to *trans*-dioxadecalins.

*Alkynol Cycloisomerisation of 4-Ethynyl-D-glucopyranosides.* The buta-1,3-diyne **30** (82%), the bromide **32** (83%), and the iodide **33** (73%; *Scheme 4*) were prepared from the 4-ethynyl-1-thio- $\beta$ -D-glucopyranoside **29** [44], similarly as described for the synthesis of **22–24**. The chloride **31** was obtained in 64% yield by lithiation of **29** in



*a*) (Bromoethynyl)benzene,  $[\text{Pd}_2(\text{dba})_3]$ , CuI, P(fur)<sub>3</sub>, Et<sub>3</sub>N, DMF; 82% of **30**, 82% of **39**. *b*) BuLi, then NCS, THF; 64% of **31**. *c*) NBS, AgNO<sub>3</sub>, THF; 83% of **32**. *d*) NIS, AgNO<sub>3</sub>, NH<sub>3</sub>/H<sub>2</sub>O, acetone; 73% of **33**. *e*) MeONa, MeOH, reflux; 76% of **34**, 63% of **35**, 74% of **36**, 64% of **37**, 30% of **40**, and 51% of **41**. *f*) Cu(OAc)<sub>2</sub>, pyridine; 88%. *g*) NaOH, THF/MeOH/H<sub>2</sub>O, 60°; 99%. *h*) Na<sub>2</sub>S · 9 H<sub>2</sub>O, 2-methoxyethanol; 20% of **44** and ca. 10% of an unassigned 4 : 3 : 2 mixture.



THF with BuLi at  $-78^\circ$ , followed by chlorination with NCS. Treatment of **30–33** with MeONa in boiling MeOH for 4 h led to deacetylation and selective cyclisation of the intermediate triols to the *gluco*-configured exocyclic enol ethers **34–37** (63–76%).

The buta-1,3-diyne **39** (82%) was obtained by *Sonogashira* coupling of 4-ethynyl-1-thio- $\alpha$ -D-glucopyranoside **38** [30] and (bromo-ethynyl)benzene, while *Eglinton* coupling of **38** yielded 88% of the  $C_2$ -symmetric acetylated buta-1,3-diyne **42** (Scheme 4). MeONa in MeOH (4 h at reflux) transformed the acetate **39** into the corresponding alcohol, which cyclised *in situ* to the *galacto*-configured (*Z*)- and (*E*)-ynenol ethers **40** (30%) and **41** (51%). Treatment of the diyne **42** with NaOH in THF/MeOH/H<sub>2</sub>O for 15 min at  $60^\circ$  led in 99% yield to the diol **43**. Boiling the diol **43** and Na<sub>2</sub>S · 9 H<sub>2</sub>O in 2-methoxyethanol for 30 min led to the *gluco*- and *galacto*-configured enol ether **44** (20%), and to a 4 : 3 : 2 mixture of alkenes (*ca.* 10%) that were not isolated<sup>7</sup>). Heating **43** in 2-methoxymethanol in the presence of excess K<sub>2</sub>CO<sub>3</sub> or treatment of **43** with NaH in DMF at  $0^\circ$  did not afford **44**.

The *gluco*-configuration of **30–37**, **39**, **42**, **43**, and of the directly alkynylated moiety of **44** is evidenced by large  $J(3,4)$  and  $J(4,5)$  values (9.7–11.1 Hz), whereas the *galacto*-configuration of **40** and **41** is revealed by distinctly smaller  $J(3,4)$  and  $J(4,5)$  values (3.4–7.0 Hz; see Tables 5 and 6 in the *Exper. Part*). In agreement with the *galacto*-configuration, the olefinic H–C(2') of **44** resonates as a br. *s* showing a  $w_{1/2}$  value of 8.7 Hz. The *trans*-annulation of **34–37** is also evidenced by large  $J(5,6a)$  and  $J(5,6b)$  values (6.6–6.7 and 9.6–9.7 Hz, resp.) whereas small  $J(5,6a)$  and  $J(5,6b)$  values (0–4.2 Hz) reveal the *cis*-annulation of **40**, **41**, and **44**. Characteristic geminal  $J(6a,6b)$  values (**34–37**: 7.8–8.0; **40**, **41**, and **44**: 10.0–10.1 Hz) reflect the different orientation of both H–C(6) and the lone pairs at O–C(6) (cf. [45]). The *galacto*-configuration of **40** and **41** was corroborated by NOEs between H–C(3) and H–C(4) (7.5–12%; see *Exper. Part*).

The olefinic H-atom of the *gluco*-configured enol ethers **34–37** resonates as a *d* at 5.15–5.45 ppm (Table 5 in the *Exper. Part*). The chemical shift depends only weakly on the substituents and evidences that **34–37** possess the same configuration of the C=C bond.  $J(4,CH=C)$  of 2.1–2.4 Hz is compatible with an allylic coupling of an exocyclic enol ether, but also with a vicinal coupling of an endocyclic enol ether (according to MM3\* calculation both couplings are 2.6 Hz). An endocyclic enol ether may, however, be excluded as it should show similar  $J(5,6_{eq})$ ,  $J(5,6_{ax})$ , and  $J(6_{eq},6_{ax})$  values as the corresponding 4,6-*O*-benzylidene acetal (typically 4.5, 10.5, and 10.5 Hz, resp.). The olefinic H-atom of the *galacto*-configured enol ethers **40** and **41** resonates as a *d* at 5.98 and 5.34 ppm, respectively (Table 6 in the *Exper. Part*). The large  $\Delta\delta$  value (0.64 ppm) is suggestive of an (*E*)/(*Z*)-pair. Since the olefinic H-atom of both isomers is close to an O-atom ((*Z*)-isomer to BnO–C(4); (*E*)-isomer to O–C(6)), the relative deshielding does not allow an unambiguous assignment of the configuration although a comparison with the *gluco* analogue **34** suggests the (*Z*)-configuration for **40**. Moreover, the coupling of the olefinic H-atom with H–C(4) (**40**: 2.2, **41**: 1.9 Hz) and the small  $J(5,6_{eq})$  and  $J(5,6_{ax})$  values of **40** (0 and 2.2 Hz, resp.) do not allow to exclude the structure of an endocyclic enol ether. The structure of an exocyclic enol ether is, however, evidenced by cross-peaks in the HMBC spectrum of **40** between H–C(3) and the *s* at 164.23 ppm, between H–C(5) and the *s* at 164.23 ppm, and between H–C(2') and C(1)/C(2)/C(6) of the PhC≡C moiety. Similar cross-peaks are missing in the HMBC spectrum of **41**, but here  $J(5,6_a) = 3.1$  and  $J(5,6_b) = 6.0$  Hz exclude an endocyclic enol ether (according to MM3\* calculation  $J(5,6_a) = 1.0$  and  $J(5,6_b) = 3.0$  Hz). The (*Z*)-configuration of **40** was evidenced by NOEs for H–C(4) (2.6%) and H–C(2) (2.4%) observed upon irradiation of H–C(2'). As expected, no NOE was observed upon irradiation of H–C(2') of the (*E*)-configured **41**. In addition, the C(1') *s* of the enol ether moiety of **40** and **41** show the same relative shifts (**40**: 164.2, **41**: 168.6 ppm) as the (*Z*)- and (*E*)-lactone oximes and hydrazones (cf. [46–48]). H–C(2') of the dimer **44** resonates as a *t* at 5.31 ppm. It shows an allylic coupling with H–C(4<sub>Gai</sub>) and a homopropargylic coupling with H–C(4<sub>Gic</sub>) (both 1.5 Hz). Signal overlap for H–C(2), H–C(3), H–C(5), and H<sub>a</sub>–C(6) of the galactose unit of **44** prevents an assignment of  $J(2,3)$ ,  $J(3,4)$ ,  $J(4,5)$ , and  $J(5,6_a)$ , while the similarity of

7) The <sup>1</sup>H-NMR spectrum of this mixture showed two signals at 5.18 and 5.14 ppm for olefinic H-atoms, and two signals at 3.33 and 2.92 ppm for H–C(4) of the glucopyranosyl residues.

$\delta(\text{H}-\text{C}(2))$  and  $J(5,6)$  of the galactose unit of **44** and the corresponding values of **40** indicates the (*Z*)-configuration.

The conformations of the pyranose ring of **40** and **41** differ. A flattened  ${}^4C_1$  is evidenced for the (*Z*)-configured **40** by  $J(1,2) = 4.8$ ,  $J(2,3) = 10.0$ ,  $J(3,4) = 5.6$ , and  $J(4,5) = 3.4$  Hz (Table 6 in the *Exper. Part*). The  ${}^4C_1$  conformer of the (*Z*)-configured **41** is destabilised by a steric interaction between  $\text{PhC}\equiv\text{C}$  and both  $\text{BnO}$  groups, and a boat conformation is preferred. MM3\* modeling of the  ${}^0S_2$  conformer of **41** predicts vicinal coupling constants that are similar to the experimentally determined ones.


Only products of a formal 5-*exo-dig* alkynol cycloisomerisation of **30–33**, **39**, and **43** were observed. There is a striking difference between the  $\beta$ -D-glucopyranosides **30–33** affording only the *gluco*-configured (*Z*)-enol ethers and the  $\alpha$ -D-glucopyranosides **39** and **43** affording a (*E*)/(*Z*) mixture of the *galacto*-configured enol ethers. We assume that this difference results from a neighbouring group participation of  $\text{HO}-\text{C}(3)$  and not from the different anomeric configuration, cyclisation to a strained *trans*-dioxahexahydroindan being favoured by concerted protonation of the evolving vinyl anion by  $\text{HO}-\text{C}(3)$  of the intermediate triols derived from **30–33**. In the absence of this intramolecular protonation, the alcohol derived from **39** (and similarly **43**) may equilibrate with the allenes **A** and further with the *galacto* isomer **B** (Scheme 4). The allenes **A** may cyclise to the *cis*-dioxahexahydroindans **40** and **41** by a 5-*exo-dig* process, leading to an intermediate dihydrofuran that isomerises to the product by migration of the double bond. Such a process appears more probable than a direct 5-*endo-dig* cyclisation<sup>8)9)</sup>. Alternatively, the *galacto*-configured buta-1,3-diyne **B** may cyclise to the *cis*-dioxahexahydroindans **40** and **41**. It is not clear why this cyclisation with  $\text{NaOMe}$  in  $\text{MeOH}$  (concerted intermolecular protonation of the emerging vinyl anion) leads preferentially to the sterically disfavoured **41**, unless protonation leading to **41** is (sterically?) favoured.

*Alkynol Cycloisomerisation of  $\beta$ -D-Galactopyranosylethynes.* The configuration at C(1) and C(4) of the  $\alpha$ -D-glucopyranosylethynes (Scheme 2) and of the  $\beta$ -D-galactopyranosylethynes **49–51** (Scheme 5) differ, but the alkynyl and the hydroxy substituents of all these compounds are *cis*-oriented. One expects that the galactopyranosyl C-glycosides **49–51** will cyclise about as readily as the *gluco*-alkynols **14** and **15** and lead to epimeric 1,5-dioxabicyclo[2.2.2]octanes. The  $\beta$ -D-galactopyranosylethyne **49** was prepared from the diol **45** [63] by standard reactions. 4-Methoxybenzylation of **45** ( $\rightarrow$  **46**), deallylation ( $\rightarrow$  **47**), and *Swern* oxidation yielded the galactono-1,5-lactone **48** in 65% overall yield. The anomeric 1-ethynylated galactopyranoses were obtained

<sup>8)</sup> Treatment of allenic alcohols with various bases induces a 5-*exo-dig* cyclisation to endocyclic enol ethers by attack on the central *sp* hybridised C-atom of the allenyl moiety [49–52]. However, treatment of (–)-marasin, a buta-1,3-diynebutenyl allenylethanol, with aqueous  $\text{NaOH}$  resulted in the formation of (*Z*)-2-(penta-2,4-diynebutenylidene)oxolane [53][54]. The protic and *Lewis* acid (silver salts or  $\text{BF}_3$ ) catalysed 5-*endo-dig* and 6-*endo-dig* cyclisation of  $\alpha$ - and  $\beta$ -allenic alcohols to 2,5-dihydrofurans and 3,6-dihydro-2*H*-pyrans have been described (see [55–57]). The  $\text{HgO}$ - or  $\text{Pd}(\text{PPh}_3)_4$ -catalysed allenol cycloisomerisation gave *endo*- [58][59] and *exocyclic* enol ethers [60].

<sup>9)</sup> A 5-*exo-dig* cyclisation, followed by migration of the double bond, or a 5-*endo-dig* cyclisation appears more probable than isomerisation to the corresponding triynol, followed by a 5-*exo-dig* cyclisation, considering that distillation of pent-4-yn-1-ol (possessing an isolated, non-activated  $\text{C}\equiv\text{C}$  bond) in the presence of a catalytic amount of  $\text{NaNH}_2$  gave 2-methylideneoxolane [61][62].

by treating **48** with lithium (trimethylsilyl)acetylide and reduced with  $\text{Et}_3\text{SiH}$  and  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ . Under these conditions, the 4-methoxybenzyl ethers were also cleaved (compare [64]) and the diol **49** was isolated in 63% yield. *C*-Desilylation ( $\text{NaOMe}$  in  $\text{MeOH}$ ) to **50** and *Sonogashira* coupling with (bromoethynyl)benzene gave 85% of the buta-1,3-diyne **51**. Bromination of **50** with  $\text{NBS}$  and  $\text{AgNO}_3$  in  $\text{THF}$  at room temperature led to the bromoacetylene which cyclised *in situ* to the enol ether **52** (93%). Cyclisation of **51** ( $\text{NaOMe}$  in  $\text{MeOH}$ ) yielded 93% of the ynenol ether **53** which was acetylated to **54** (95%).




a)  $\text{PMBCl}$  (= 4-methoxybenzyl chloride),  $\text{NaH}$ ,  $\text{DMF}$ ; 90%. b)  $[\text{Ir}(\text{COD})(\text{PPh}_2\text{Me})\text{PF}_6]$ ,  $\text{H}_2$ ,  $\text{THF}$ , then  $\text{I}_2$  and  $\text{H}_2\text{O}$ ; 82%. c)  $\text{DMSO}/\text{Ac}_2\text{O}$  2 : 1; 88%. d)  $\text{BuLi}$ ,  $\text{Me}_3\text{SiC}\equiv\text{CH}$ ,  $\text{THF}$ ;  $\text{Et}_3\text{SiH}$ ,  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2/\text{MeCN}$  1 : 1; 63%. e)  $\text{MeONa}$ ,  $\text{MeOH}$ ; 93%. f) (Bromoethynyl)benzene,  $[\text{Pd}_2(\text{dba})_3]$ ,  $\text{CuI}$ ,  $\text{P}(\text{fur})_3$ ,  $\text{Et}_3\text{N}$ ,  $\text{DMF}$ ; 85%. g) **50**,  $\text{NBS}$ ,  $\text{AgNO}_3$ ,  $\text{THF}$ ; 93% of **52**. h) **51**,  $\text{MeONa}$ ,  $\text{MeOH}$ ; 93% of **53**. i)  $\text{Ac}_2\text{O}$ , pyridine; 95%.

The  $\beta$ -D-configuration of the galactopyranosylethynes **49–51** is evidenced by  $J(1,2) = 9.6–9.9$  Hz (Table 7 in the *Exper. Part*).  $\text{HO}-\text{C}(4)$  of **49–51** resonates as a *dd* at 2.64–2.70 ppm. In  $\text{CDCl}_3$ , the small  $J(4,\text{OH}) = 1.5–2.0$  Hz and the *W*-coupling with  $\text{H}-\text{C}(5)$  (1.0–1.5 Hz) evidence an intramolecular H-bond of  $\text{HO}-\text{C}(4)$  to  $\text{BnO}-\text{C}(3)$  (cf. [65]).  $J(6_b,\text{OH}) = 7.2–8.4$  Hz, and  $J(6_s,\text{OH}) = 3.3–4.8$  Hz of the diols **49–51** and the monoalcohols **52** and **53** reveal an intramolecular H-bond of  $\text{HO}-\text{C}(6)$  to  $\text{O}-\text{C}(5)$ . The enol ether moiety of **52–54** is evidenced by an IR band at 1658–1664  $\text{cm}^{-1}$ . The small coupling between the olefinic H-atom and  $\text{H}-\text{C}(1)$  of **52–54** ( $\leq 1.0$  Hz) reveals the dioxabicyclo[2.2.2]octane structure, and allows us to exclude a dioxabicyclo[3.2.2]nonane structure (cf. *Sect. 2.1*). The upfield shift of  $\text{H}-\text{C}(1)$  at 4.24–4.29 ppm evidences the (*Z*)-configuration of **52–54**, which is corroborated by NOEs of 9–14% between  $\text{H}-\text{C}(1)$  and  $\text{H}-\text{C}(2')$  of **53** (see *Exper. Part*).

As expected from the cyclisation of the  $\alpha$ -D-*gluco*-analogues **15** and **16**, a 6-*exo-dig* alkynol cycloisomerisation of **51** and the corresponding bromoacetylene required the conformational change from  ${}^4C_1$  to  ${}^{1,4}B$ , and the bromoacetylene cyclised already under the mild conditions of its preparation. No 2-methylidene-3,9-dioxabicyclo[3.3.2]nonane resulting from a 6-*exo-dig* alkynol cycloisomerisation involving the primary OH group and requiring a change of the ring conformation from  ${}^4C_1$  to  ${}^1C_4$  was found.

*Attempted Alkynol Cycloisomerisation of 4-Ethynylated Levoglucosans.* We explored the limits of strain compatible with alkynol cyclisation by attempting to cyclise the 4-ethynylated levoglucosan derivatives **56**–**58**, which are easily accessible from the known diol **55** [66] (Scheme 6). Due to the short CH<sub>2</sub>O bridge in levoglucosans, the distance between the axial substituents at C(2) and C(4) is considerably larger than the typical distance between 1,3-diaxial substituents of cyclohexane (*anti*-reflex effect; see [67] and refs. cit. therein). Thus, the O...O distance between the 1,3-diaxial OH groups is 3.299 Å in crystalline levoglucosan, but only 2.768 Å in crystalline 1,3,5-methylidyne-*myo*-inositol [67]. A 5-*endo-dig* alkynol cycloisomerisation of 4-ethynylated levoglucosans would lead to a severely strained *anti*-2,8,9-trioxatricyclo[4.2.1.1<sup>2,5</sup>]decane<sup>10)</sup>.

Scheme 6



a) (Bromoethynyl)benzene, [Pd<sub>2</sub>(dba)<sub>3</sub>], CuI, P(fur)<sub>3</sub>, Et<sub>3</sub>N, DMF; 76% of **56**. b) NBS, AgNO<sub>3</sub>, THF; 92% of **57**. c) NIS, AgNO<sub>3</sub>, NH<sub>3</sub>, acetone/H<sub>2</sub>O; 87% of **58**. d) MeONa or *t*-BuOK, MeOH; 82% of **59**, 62% of **60**, 68% of **61**.

The solid-state structure of **57** was determined by X-ray analysis (Fig. 2)<sup>6)</sup>. The distance between O–C(2) and C(1') is 3.196 Å. HO–C(2) is involved in a intramolecular H-bond to OC(5) (OH...OC(5) distance 2.395 Å, H–C(2)–O–H dihedral angle –159.6°), whereas HO–C(3) is engaged in an intermolecular H-bond to O–C(6). The ethynyl moiety does not act as additional H-acceptor of the intermolecular H-bond revealed by the OH...C(1') distance of 2.732 Å. It is slightly bent, as indicated by the bond angles for C(4)–C(1')–C(2') and C(1')–C(2')–Br of 175.6 and 177.8°, respectively.

Treatment of the buta-1,3-diyne **56** with MeONa in MeOH gave the dienenitol **59** in 82% yield. A similar treatment of the bromide **57** and the iodide **58** (with *t*-BuOK instead of MeONa) led to a 9 : 1 mixture of the epimeric bromoallenes **60** (82%) and to a 1 : 1 mixture of the epimeric iodoallenes **61** (68%). As expected, no cyclisation products could be found in the crude products obtained from **56**–**58**.

In CDCl<sub>3</sub> solution, HO–C(2) of **56**–**58** is engaged in a bifurcated intramolecular H-bond to O–C(5) and the acetylene group as evidenced by  $J(2,\text{OH}) = 11.8$ – $11.9$  Hz, and HO–C(3) forms an intramolecular H-bond to O–C(6) ( $J(3,\text{OH}) = 7.7$ – $7.8$  Hz).  $J(2,\text{OH})$  of **59** = 11.2 Hz evidences in solution a bifurcated intramolecular

<sup>10)</sup> *anti*-2,8,9-Trioxatricyclo[4.2.1.1<sup>2,5</sup>]decanes are not known. *anti*-2,8,9-Tricyclo[4.2.1.1<sup>2,5</sup>]decane is 23.7 kcal/mol higher in energy than the isomeric adamantane [68].




Fig. 2. Crystal structure of the 4-ethynylated levoglucosans **57** and **59**

H-bond to O–C(5) and the C=C bond. In the solid state of **59**, however, HO–C(2) is involved only in intermolecular H-bonding (Fig. 2).  $J(2,\text{OH})$  and  $J(3,\text{OH})$  values of the allenes **60** and **61** are 8.2–8.7 and 6.8–7.1 Hz, and evidence intramolecular H-bonds to O–C(5) and O–C(6), respectively. The C=CH group of **59** is evidenced by the IR band at  $1680\text{ cm}^{-1}$ , the downfield shift of H–C(3) at 6.23 ppm, and the downfield shift of C(3) (*d* at 133.5 ppm) and C(4) (*s* at 125.36 ppm). The allenyl moieties of **60** and **61** show the expected spectroscopic characteristics (*cf.* [69]); *i.e.*, an IR band at  $1964$  and  $1955\text{ cm}^{-1}$ , a strong downfield shift of C(1') at 198.6 and 201.0 ppm, a weak upfield shift for C(4) at 108.6 and 102.1 ppm, and a strong upfield shift for C(2') at 73.1/73.2 and 39.0/38.3 ppm, respectively.

**Conclusions.** – Base-promoted alkynol cycloisomerisation of hydroxybuta-1,3-diyne and haloalkynes occurs readily, and a 5- or a 6-*exo-dig* ring closure to *exo*-methylidene-tetrahydrofurans and -pyrans is preferred. If this ring closure is disfavoured by ring strain, isomerisation to the isomeric allenes is preferred over an alkynol cycloisomerisation. In keeping with earlier work on non-carbohydrate alkynols, our results show that alkynol cycloisomerisation is favoured by cumulated triple bonds, a 1-iodo 1-bromo, 1-chloro, 1-phenylchalcogeno (S or Se), or 1-(hetero)aryl substituent, and the proximity of the reacting groups [11][12]. Alkynol cycloisomerisation promises to become a useful additional route to (further functionalised) *exo*-glycals.

We thank Dr. B. Schweizer for the crystal-structure determination, C. Jäger for the help in the synthesis of the *galacto*-dimers, and the Swiss National Science Foundation and F. Hoffmann-La Roche AG, Basel, for generous support.

#### Experimental Part

*General.* See [30].

*1,1'-[Buta-1,3-diyne-1,4-diyl]bis[2,3,6-tri-O-benzyl- $\alpha$ -D-glucopyranosyl]* (**15**). Under Ar, a soln. of  $\text{Cu}(\text{OAc})_2$  (11.9 g, 65.7 mmol) in pyridine (110 ml) was heated to  $60^\circ$ , stirred for 3 h, treated with a soln. of **14** [30] (11.9 g, 65.7 mmol) in pyridine (10 ml), stirred for 1 h, and evaporated. Pyridine was removed by co-

evaporation with toluene. FC (hexane/AcOEt 5 : 1 → 1 : 1) gave **15** (1.24 g, 83%).  $R_f$  (hexane/AcOEt 3 : 1) 0.28.  $[\alpha]_D^{25} = +189.2$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3587 $m$ , 3510 $w$ , 3089 $w$ , 3066 $w$ , 2913 $m$ , 2871 $m$ , 2157 $w$ , 1603 $w$ , 1496 $m$ , 1454 $m$ , 1364 $m$ , 1330 $m$ , 1248 $m$ , 1069 $s$ , 1028 $s$ , 910 $w$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): 7.42–7.24 ( $m$ , 15 arom. H); 5.03 ( $d$ ,  $J = 11.4$ , PhCH); 4.81 ( $d$ ,  $J = 5.8$ , H–C(1)); 4.78 ( $d$ ,  $J = 11.1$ ), 4.73 ( $d$ ,  $J = 12.0$ ), 4.69 ( $d$ ,  $J = 12.0$ ), 4.59 ( $d$ ,  $J = 12.3$ ), 4.54 ( $d$ ,  $J = 12.0$ ) (5 PhCH); 3.95 (br.  $dt$ ,  $J \approx 9.6$ , 3.9, H–C(5)); 3.79 ( $t$ ,  $J = 9.1$ , H–C(3)); 3.73 ( $dd$ ,  $J = 10.5$ , 4.2, H–C(6)); 3.69 ( $dd$ ,  $J = 10.5$ , 3.3, H'–C(6)); 3.615 ( $dd$ ,  $J = 9.3$ , 5.8, H–C(2)); 3.62 ( $td$ ,  $J = 9.2$ , 2.3, addn. of  $\text{D}_2\text{O} \rightarrow t$ ,  $J = 9.2$ , H–C(4)); 2.44 ( $d$ ,  $J = 2.3$ , exchange with  $\text{D}_2\text{O}$ , HO–C(4)).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): 138.59, 137.74, 137.55 (3 $s$ ); 128.50–127.66 (several  $d$ ); 82.54 ( $d$ , C(3)); 78.52 ( $d$ , C(2)); 75.54, 73.72, 73.02 (3 $t$ , 3 PhCH<sub>2</sub>); 74.81 ( $s$ , C≡C–C(1)); 73.15 ( $s$ , C≡C–C(1)); 73.89 ( $d$ , C(5)); 70.54 ( $d$ , C(4)); 69.44 ( $t$ , C(6)); 67.44 ( $d$ , C(1)). HR-MALDI-MS: 937.391 ( $[M + \text{Na}]^+$ ,  $\text{C}_{58}\text{H}_{58}\text{NaO}_{10}$ ; calc. 937.392).

(7Z)-2,6 : 3,7 : 11,15-Trihydro-1,4,5,12,13,16-hexa-O-benzyl-8,9,10-trideoxy-D-erythro-L-ido-L-gulo-hexadec-7-en-9-ynitol (**16**). a) A soln. of **15** (355 mg, 0.38 mmol) in  $\text{MeOCH}_2\text{CH}_2\text{OH}$  (10 ml) was treated with  $\text{Na}_2\text{S} \cdot 9 \text{H}_2\text{O}$  (745.5 mg, 3.10 mmol), stirred for 40 min under reflux, cooled to 23°, diluted with AcOEt (0.5 ml) and hexane (0.8 ml), stirred for 30 min, and filtered through *Celite*. Evaporation of the filtrate and FC (hexane/AcOEt 10 : 1 → 3 : 1) gave **16** (212 mg, 60%).

b) A soln. of **15** (20 mg, 22 μmol) in  $\text{MeOCH}_2\text{CH}_2\text{OH}$  (3 ml) was treated with  $\text{K}_2\text{CO}_3$  (24 mg, 0.17 mmol), kept for 24 h at reflux, and evaporated. A soln. of the residue in AcOEt (10 ml) was washed with  $\text{H}_2\text{O}$  (5 ml), dried ( $\text{MgSO}_4$ ), and evaporated. FC (hexane/AcOEt 10 : 1 → 3 : 1) gave **16** (14 mg, 70%).  $R_f$  (hexane/AcOEt 3 : 1) 0.85.  $[\alpha]_D^{25} = +150.6$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3590 $w$ , 3066 $w$ , 2917 $m$ , 2870 $m$ , 2209 $w$ , 1661 $m$ , 1603 $w$ , 1496 $m$ , 1454 $m$ , 1335 $m$ , 1094 $s$ , 1027 $s$ , 909 $w$ .  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ , assignment based on a DQF-COSY-GRASP and a HSQC-GRASP spectrum): 7.38–7.22 ( $m$ , 30 arom. H); 4.98 ( $d$ ,  $J = 11.1$ , PhCH); 4.98 ( $dd$ ,  $J = 5.5$ , 2.0, H–C(11)); 4.75 ( $d$ ,  $J = 11.4$ ), 4.72 ( $d$ ,  $J = 11.9$ ), 4.65 ( $d$ ,  $J = 11.8$ ) (3 PhCH); 4.66 ( $d$ ,  $J = 2.0$ , irradi. at 4.09 → NOE of 14%, H–C(8)); 4.59 ( $d$ ,  $J = 12.1$ ), 4.45 ( $s$ , irradi. at 4.09 → NOE of 5%, 2 H), 4.53 ( $d$ ,  $J = 11.4$ , 2 H), 4.49 ( $d$ ,  $J = 11.9$ ), 4.47 ( $d$ ,  $J = 11.6$ ), 4.41 ( $d$ ,  $J = 11.9$ ) (8 PhCH); 4.43–4.42 ( $m$ , H–C(3)); 4.38 (br.  $t$ ,  $J \approx 6.5$ , H–C(2)); 4.09 ( $dd$ ,  $J = 3.5$ , 1.9, with virtual coupling, irradi. at 4.61 → NOE of 8%, H–C(6)); 4.01 ( $dt$ ,  $J \approx 9.6$ , 3.9, H–C(15)); 3.91–3.89 ( $m$ , irradi. at 4.09 → NOE of 7%, H–C(4), H–C(5)); 3.82 ( $t$ ,  $J = 9.1$ , H–C(13)); 3.73 ( $dd$ ,  $J = 10.7$ , 4.2, H–C(16)); 3.68 ( $dd$ ,  $J = 10.6$ , 3.4, H'–C(16)); 3.65 ( $d$ ,  $J = 6.4$ , 2 H–C(1)); 3.63 ( $dd$ ,  $J = 9.4$ , 5.6, H–C(12)); 3.61 (br.  $t$ ,  $J = 8.8$ , H–C(14)); 2.40 ( $d$ ,  $J = 1.7$ , HO–C(14)).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ , assignment based on a HSQC-GRASP spectrum): 159.55 ( $s$ , C(7)); 138.92, 138.32, 137.06, 137.90, 137.52, 137.35 (6 $s$ ); 128.32–127.47 (several  $d$ ); 87.44 ( $s$ , C(10)); 83.56 ( $s$ , C(9)); 83.43 ( $d$ , C(8)); 82.20 ( $d$ , C(13)); 80.55, 79.53 (2 $d$ , C(4), C(5)); 78.71 ( $d$ , C(12)); 75.41 ( $d$ , C(2)); 75.12, 73.37, 73.15, 72.28, 71.77, 71.43 (6 $t$ , 6 PhCH<sub>2</sub>); 72.79 ( $d$ , C(15)); 70.99 ( $d$ , C(3)); 70.64 ( $d$ , C(14)); 69.76 ( $t$ , C(1)); 69.52 ( $t$ , C(16)); 69.04 ( $d$ , C(6)); 67.27 ( $d$ , C(11)). HR-MALDI-MS: 937.393 ( $[M + \text{Na}]^+$ ,  $\text{C}_{58}\text{H}_{58}\text{NaO}_{10}$ ; calc. 937.392).

(7Z,9Z)-2,6 : 3,7 : 10,14 : 11,15-Tetrahydro-1,4,5,12,13,16-hexa-O-benzyl-8,9-dideoxy-D-erythro-L-ido-L-gulo-hexadeca-7,9-dienitol (**17**). a) A soln. of **16** (27 mg, 29.5 μmol) in  $\text{MeOCH}_2\text{CH}_2\text{OH}$  (3 ml) was treated with  $\text{K}_2\text{CO}_3$  (40.7 mg, 0.29 mmol), kept for 48 h at reflux, and evaporated. A soln. of the residue in AcOEt (10 ml) was washed with  $\text{H}_2\text{O}$  (8 ml), and the aq. layer was extracted with AcOEt (3 × 10 ml). The combined org. layers were washed with brine, dried ( $\text{MgSO}_4$ ), and evaporated. FC (hexane/AcOEt 10 : 1 → 3 : 1) gave **17** (10 mg, 37%).

b) A soln. of **16** (20 mg, 21.9 μmol) in  $\text{MeOCH}_2\text{CH}_2\text{OH}$  (2 ml) was treated 1M  $\text{MeOCH}_2\text{CH}_2\text{ONa}$  in  $\text{MeOCH}_2\text{CH}_2\text{OH}$  (200 μl, 0.22 mmol), kept for 70 h at reflux, and evaporated. A soln. of the residue in AcOEt (10 ml) was washed with  $\text{H}_2\text{O}$  (8 ml), and the aq. layer was extracted with AcOEt (3 × 10 ml). The combined org. layers were washed with brine, dried ( $\text{MgSO}_4$ ), and evaporated. FC (hexane/AcOEt 10 : 1 → 3 : 1) gave **17** (2 mg, 10%).  $R_f$  (hexane/AcOEt 3 : 1) 0.62.  $[\alpha]_D^{25} = +139.2$  ( $c = 0.5$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3089 $w$ , 3066 $w$ , 2961 $m$ , 2869 $m$ , 1654 $m$ , 1604 $w$ , 1496 $m$ , 1454 $m$ , 1363 $m$ , 1324 $m$ , 1261 $s$ , 1101 $s$ , 1027 $s$ , 909 $w$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): 7.39–7.23 ( $m$ , 15 arom. H); 5.39 ( $s$ , H–C(8)); 4.60 ( $d$ ,  $J = 12.3$ ), 4.55 ( $d$ ,  $J = 12.0$ ), 4.51 ( $d$ ,  $J = 12.0$ ), 4.50 ( $d$ ,  $J = 12.0$ ), 4.49 ( $d$ ,  $J = 11.9$ ), 4.41 ( $d$ ,  $J = 12.0$ ) (6 PhCH); 4.41–4.34 ( $m$ , H–C(2), H–C(3)); 4.14 ( $d$ ,  $J = 3.0$ , H–C(6)); 3.92–3.86 ( $m$ , H–C(4), H–C(5)); 3.65 ( $d$ ,  $J \approx 6.0$ , 2 H–C(1)).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): 146.59 ( $s$ , C(7)); 137.91, 137.63, 137.47 (3 $s$ ); 128.33–127.56 (several  $d$ ); 97.88 ( $d$ , C(8)); 81.17, 79.70 (2 $d$ , C(4), C(5)); 75.93 ( $d$ , C(2)); 73.21, 71.68, 71.17 (3 $t$ , 3 PhCH<sub>2</sub>); 70.58 ( $d$ , C(3)); 70.05 ( $t$ , C(1)); 69.86 ( $d$ , C(6)). HR-MALDI-MS: 937.391 ( $[M + \text{Na}]^+$ ,  $\text{C}_{58}\text{H}_{58}\text{NaO}_{10}$ ; calc. 937.392).

*Benzylation of 15.* Under Ar, a soln. of **15** (737 mg, 0.80 mmol) in DMF (36 ml) was cooled to 0°, treated with 60% NaH in oil (270 mg, 8.0 mmol), stirred for 15 min, treated with BnBr (478 μl, 5.02 mmol), stirred for 3 h, treated dropwise with MeOH (1.0 ml), and diluted with  $\text{H}_2\text{O}$  (30 ml) and  $\text{Et}_2\text{O}$  (50 ml). After separation of the layers, the aq. layer was extracted with  $\text{Et}_2\text{O}$  (2 × 50 ml). The combined org. layers were washed with brine, dried ( $\text{MgSO}_4$ ), and evaporated. FC (hexane/ $\text{Et}_2\text{O}$  10 : 1 → 5 : 1) gave **18** (391 mg, 53%) and **19** (155 mg, 21%).

Data of (Z)-2,6:3,7:11,15-Trihydro-1,4,5,12,13,14,16-hepta-O-benzyl-8,9,10-trideoxy-D-erythro-L-ido-L-gulo-hexadeca-7-en-9-ynitol (**18**).  $R_f$  (hexane/AcOEt 3:1) 0.70.  $[\alpha]_D^{25} = +166.4$  ( $c = 0.5$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3088w, 3066w, 2917m, 2867m, 2209w, 1662m, 1496m, 1454m, 1363m, 1089s, 1027s, 910w.  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ; assignment based on a HSQC.GRASP spectrum): 7.38–7.21 (*m*, 33 arom. H); 7.14–7.13 (*m*, 2 arom. H); 4.98 (*d*,  $J = 11.2$ , PhCH); 4.97 (*dd*,  $J = 5.6$ , 2.0, H–C(11)); 4.84 (*d*,  $J = 10.6$ ), 4.81 (*d*,  $J = 10.9$ ), 4.72 (*d*,  $J = 11.9$ ), 4.68 (*d*,  $J = 11.9$ ) (4 PhCH); 4.64 (*d*,  $J = 2.0$ , H–C(8)); 4.62 (*d*,  $J = 12.1$ ), 4.54 (*s*, 2 H), 4.51 (*d*,  $J = 11.6$ ), 4.48 (*d*,  $J = 11.0$ , 2 H), 4.47 (*d*,  $J = 12.1$ ), 4.45 (*d*,  $J = 11.6$ ), 4.41 (*d*,  $J = 12.0$ ) (9 PhCH); 4.43–4.42 (*m*, H–C(3)); 4.38 (*br. t*,  $J \approx 6.8$ , H–C(2)); 4.07 (*dd*,  $J = 2.0$ , 1.4, with virtual coupling, H–C(6)); 4.04 (*ddd*,  $J = 9.9$ , 3.3, 2.1, H–C(15)); 3.99 (*t*,  $J = 9.2$ , H–C(13)); 3.89–3.88 (*m*, H–C(4), C(5)); 3.77 (*dd*,  $J = 10.8$ , 3.5, H–C(16)); 3.68 (*dd*,  $J = 10.8$ , 2.0, H–C(16)); 3.65 (*dd*,  $J = 9.4$ , 5.5, H–C(12)); 3.63 (*d*,  $J = 6.7$ , 2 H–C(1)); 3.61 (*t*,  $J = 9.7$ , H–C(14)).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ; assignment based on a HSQC.GRASP spectrum): 159.57 (*s*, C(7)); 138.92, 138.32, 138.12, 138.00, 137.89, 137.51, 137.35 (7s); 128.49–127.52 (several *d*); 87.64 (*s*, C(10)); 83.60 (*s*, C(9)); 83.57 (*d*, C(8)); 83.09 (*d*, C(13)); 80.64, 79.63 (2*d*, C(4), C(5)); 79.25 (*d*, C(12)); 77.59 (*d*, C(14)); 75.60, 75.47, 75.13, 73.39, 72.57, 71.83, 71.48 (7*t*, 7 PhCH<sub>2</sub>); 75.47 (*d*, C(2)); 73.20 (*d*, C(15)); 71.03 (*d*, C(3)); 69.84 (*t*, C(1)); 69.12 (*d*, C(6)); 68.62 (*t*, C(16)); 67.34 (*d*, C(11)). HR-MALDI-MS: 1027.442 ( $[M + \text{Na}]^+$ ,  $\text{C}_{65}\text{H}_{64}\text{NaO}_{10}$ ; calc. 1027.445).

Data of (E)-2,6:3,7:11,15-Trihydro-1,4,5,12,13,14,16-hepta-O-benzyl-8,9,10-trideoxy-D-erythro-L-ido-L-gulo-hexadeca-7-en-9-ynitol (**19**).  $R_f$  (hexane/AcOEt 3:1) 0.75.  $[\alpha]_D^{25} = +65.4$  ( $c = 0.5$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3089w, 3066w, 2925m, 2868m, 2208w, 1654m, 1496m, 1454m, 1364m, 1090s, 1027s, 910w.  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ; assignment based on a DQF-COSY.GRASP and a HSQC.GRASP spectrum): 7.32–7.19 (*m*, 33 arom. H); 7.12–7.10 (*m*, 2 arom. H); 5.15 (*d*,  $J = 1.9$ , H–C(8)); 5.11 (*br. d*,  $J = 3.6$ , H–C(6)); 4.93 (*d*,  $J = 10.9$ , PhCH); 4.86 (*dd*,  $J = 5.6$ , 1.9, H–C(11)); 4.78 (*d*,  $J = 10.8$ ), 4.77 (*d*,  $J = 10.9$ ), 4.66 (*d*,  $J = 11.4$ ), 4.64 (*d*,  $J = 11.4$ ), 4.61 (*d*,  $J = 12.0$ ), 4.53 (*d*,  $J = 12.1$ ), 4.50 (*d*,  $J = 11.9$ ), 4.48 (*s*, 2 H), 4.48 (*d*,  $J = 12.0$ ), 4.43 (*d*,  $J = 11.6$ ), 4.39 (*d*,  $J = 12.2$ ), 4.27 (*d*,  $J = 11.3$ ) (13 PhCH); 4.39–4.34 (*m*, H–C(2), H–C(3)); 3.93–3.91 (*m*, H–C(15)); 3.91 (*t*,  $J = 9.1$ , H–C(13)); 3.89 (*t*,  $J = 3.5$ , irradiat. at 5.11 → *d*,  $J = 3.5$ , H–C(5)); 3.80 (*dt*,  $J = 3.4$ , 1.6, irradiat. at 4.36 → *d*,  $J = 3.4$ , H–C(4)); 3.67 (*br. d*,  $J = 6.7$ , irradiat. at 4.36 → *s*, 2 H–C(1)); 3.63 (*dd*,  $J = 10.7$ , 3.5, H–C(16)); 3.61 (*t*,  $J = 9.8$ , H–C(14)); 3.60 (*dd*,  $J = 9.4$ , 5.7, H–C(12)); 3.48 (*dd*,  $J = 10.7$ , 2.0, H–C(16)).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ; assignment based on a HSQC.GRASP spectrum): 161.76 (*s*, C(7)); 138.80, 138.30, 138.00, 137.90, 137.85, 137.40, 137.39 (7s); 128.56–127.53 (several *d*); 85.86 (*s*, C(10)); 84.59 (*s*, C(9)); 85.35 (*d*, C(8)); 83.40 (*d*, C(14)); 80.42 (*d*, C(4)); 79.04 (*d*, C(12)); 78.73 (*d*, C(5)); 77.50 (*d*, C(14)); 75.66, 75.09, 73.48, 73.44, 73.29, 72.81, 71.77 (7*t*, 7 PhCH<sub>2</sub>); 75.44 (*d*, C(2)); 73.48 (*d*, C(15)); 71.50 (*d*, C(3)); 69.97 (*t*, C(1)); 68.45 (*t*, C(16)); 67.44 (*d*, C(11)); 65.33 (*d*, C(6)). HR-MALDI-MS: 1027.438 ( $[M + \text{Na}]^+$ ,  $\text{C}_{65}\text{H}_{64}\text{NaO}_{10}$ ; calc. 1027.445).

1-O-Acetyl-5,6,7,8-tetradecoxy-2,3-O-isopropylidene- $\beta$ -D-ribo-hex-5-ynofuranose (**21**). A suspension of **20** [39] (500 mg, 2.5 mmol) in THF (5 ml) was treated with AcOH (5 ml) and Ac<sub>2</sub>O (1.4 g, 13.9 mmol), cooled to 5°, stirred for 0.5 h, treated dropwise with conc. H<sub>2</sub>SO<sub>4</sub> (0.25 ml) over a period of 5 min, and stirred at 23° for 12 h. The mixture was poured on ice (20 g), stirred for 1 h, and extracted with AcOEt (3 × 20 ml). The combined org. fractions were washed with sat. NaHCO<sub>3</sub> soln. (20 ml), H<sub>2</sub>O (20 ml) and brine (20 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/Et<sub>2</sub>O 2:1) gave **21** (460 mg, 81%). White solid.  $R_f$  (hexane/Et<sub>2</sub>O 1:1) 0.63. M.p. 75–76°.  $[\alpha]_D^{25} = -102.3$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3307m, 3029w, 2995w, 2943w, 2124w, 1746s, 1602w, 1458w, 1430w, 1376s, 1228s, 1204m, 1159m, 1104s, 1058m, 1015s, 971s, 922w, 864s.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 4; additionally, 2.01 (*s*, AcO).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): see Table 4; additionally, 169.19 (*s*, C=O); 21.08 (*q*, Me). ESI-MS: 211 ( $[M - \text{Me}]^+$ ). Anal. calc. for C<sub>11</sub>H<sub>14</sub>O<sub>5</sub> (226.23): C 58.40, H 6.24; found: C 58.24, H 6.21.

1-O-Acetyl-5,6,7,8-tetradecoxy-2,3-O-isopropylidene-8-C-phenyl- $\beta$ -D-ribo-octa-5,7-diyndofuranose (**22**). A suspension of [Pd<sub>2</sub>(dba)<sub>3</sub>] (15.7 mg, 0.0339 mmol), CuI (5.26 mg, 0.0274 mmol), P(fur)<sub>3</sub> (16 mg, 0.068 mmol), **21** (310 mg, 1.37 mmol), and (bromoethynyl)benzene (250 mg, 1.37 mmol) in DMF (5 ml) was degassed twice and stirred at 22° for 5 min. The mixture was treated with Et<sub>3</sub>N (0.7 ml) and stirred for 12 h at 22°. The soln. was diluted with Et<sub>2</sub>O (20 ml), and treated with H<sub>2</sub>O (20 ml) and 0.1M aq. HCl (5.5 ml). The org. layer was washed with H<sub>2</sub>O (2 × 15 ml), and the aq. layer was extracted with Et<sub>2</sub>O (4 × 15 ml). The combined org. fractions were dried (MgSO<sub>4</sub>) and evaporated. FC (hexane/AcOEt 4:1) gave **22** (360 mg, 81%). Pale yellow solid.  $R_f$  (hexane/AcOEt 2:1) 0.56. M.p. 86–87°.  $[\alpha]_D^{25} = -112.1$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3030w, 3014w, 2981w, 2246w, 1747s, 1491w, 1443w, 1384m, 1376m, 1227s, 1204m, 1159m, 1101s, 1054s, 1014m, 971s, 877w, 861w.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 4; additionally, 7.50–7.25 (*m*, 5 arom. H); 2.13 (*s*, AcO).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): see Table 4; additionally, 169.36 (*s*, C=O); 132.52 (2*d*); 129.48 (*d*); 128.40 (2*d*); 121.05 (*s*); 21.22 (*q*, Me). MALDI-MS: 349 ( $[M + \text{Na}]^+$ ). HR-MALDI-MS: 349.1045 ( $[M + \text{Na}]^+$ , C<sub>19</sub>H<sub>18</sub>NaO<sub>5</sub>; calc. 349.1046). Anal. calc. for C<sub>19</sub>H<sub>18</sub>O<sub>5</sub> (326.35): C 69.93, H 5.56; found: C 70.08, H 5.57.

Table 4. Selected  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR Chemical Shifts [ppm], and Coupling Constants [Hz] of the Unsaturated D-ribo-Hexofuranoses **21**–**28** in  $\text{CDCl}_3$ 

	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>	<b>26<sup>a</sup></b>	<b>25</b>	<b>27</b>	<b>28</b>
H–C(1)	6.21	6.24	6.20	6.20	5.86	5.34	5.28	5.07
H–C(2)	4.94	4.99	4.93	4.93	4.54	4.50	4.51	4.51
H–C(3)	4.82	4.84	4.81	4.81	4.44	4.41	4.41	4.41
H–C(4)	4.88	4.995	4.87	4.97	4.95	4.93	4.93	4.95
H–C(6)	2.55 <sup>b</sup>	–	–	–	4.94	5.82	5.82	5.83
Me <sub>2</sub> C	1.47, 1.33	1.48, 1.34	1.46, 1.32	1.45, 1.31	1.47, 1.32	1.46, 1.31	1.46, 1.31	1.45, 1.30
<i>J</i> (1,2)	0	0	0	0	0	0	0	0
<i>J</i> (2,3)	6.0	5.4	5.4	5.7	5.4	5.4	5.4	5.7
<i>J</i> (3,4)	0	0	0	0	0	0	0	0
C(1)	102.16	101.96	102.03	101.98	103.12	102.89	102.95	102.83
C(2)	85.21	85.07	84.98	85.18	80.62	80.67	80.71	80.74
C(3)	84.99	84.99	84.94	84.94	78.06	79.45	80.06	80.23
C(4)	75.92	76.55	76.76	77.30	78.93	78.17	77.99	77.88
C(5)	80.64	79.67	77.23	91.13	155.21	146.79	148.70	152.97
C(6)	75.24	71.82	48.01	5.12	80.09	88.58	74.53	41.57
C(7)	–	72.78	–	–	82.61	–	–	–
C(8)	–	78.63	–	–	92.43	–	–	–
Me <sub>2</sub> C	113.37	113.54	113.45	113.42	114.08	113.94	114.02	114.04
Me <sub>2</sub> C	26.40, 25.18	26.42, 25.25	26.39, 25.19	26.38, 25.19	25.99, 25.63	25.92, 25.55	25.96, 25.60	25.92, 25.57

<sup>a</sup>) Assignment based on a DQFCOSY and a HSQC spectrum, and on a NOE (2.5%) observed for H–C(2) upon irradiation of H–C(1). <sup>b</sup>)  $^4J(4,6) = 2.4$  Hz.

*1-O-Acetyl-6-C-bromo-5,6-dideoxy-2,3-O-isopropylidene-β-D-ribo-hex-5-ynofuranose (23)*. A suspension of **21** (56 mg, 0.25 mmol) and NBS (60 mg, 0.336 mmol) in acetone (3 ml) was treated with  $\text{AgNO}_3$  (6 mg, 0.036 mmol) and stirred for 30 min at 22°. After evaporation, the residue was partitioned between  $\text{H}_2\text{O}$  and AcOEt. The aq. layer was extracted with AcOEt ( $3 \times 15$  ml). The combined org. fractions were washed with brine (10 ml), dried ( $\text{MgSO}_4$ ), and evaporated. FC (hexane/AcOEt 4 : 1) gave **23** (71 mg, 95%). White solid.  $R_f$  (hexane/AcOEt 4 : 1) 0.43. M.p. 63–64°.  $[\alpha]_D^{25} = -76.8$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3027w, 3015m, 2218w, 1746s, 1376m, 1313w, 1159m, 1100s, 1055m, 1014m, 971s, 927w, 865m.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 4; additionally, 2.08 (s, AcO).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): see Table 4; additionally, 169.30 (s, C=O); 21.17 (q, Me). HR-EI-MS: 290.9689 (97,  $[M - \text{Me}]^+$ ,  $\text{C}_{10}\text{H}_{10}^{81}\text{BrO}_5$ , calc. 290.9691), 288.9715 (100,  $[M - \text{Me}]^+$ ,  $\text{C}_{10}\text{H}_{10}^{79}\text{BrO}_5$ ; calc. 288.9712). Anal. calc. for  $\text{C}_{11}\text{H}_{13}\text{BrO}_5$  (305.12): C 43.30, H 4.29; found: C 43.08, H 4.13.

*1-O-Acetyl-5,6-dideoxy-6-C-iodo-2,3-O-isopropylidene-β-D-ribo-hex-5-ynofuranose (24)*. A suspension of **21** (56 mg, 0.25 mmol) in acetone (3 ml) was added dropwise to a stirred soln. of  $\text{AgNO}_3$  (65 mg, 0.38 mmol) and diluted  $\text{NH}_3/\text{H}_2\text{O}$  (1 drop) in  $\text{H}_2\text{O}$  (3 ml). The mixture was stirred for 5 min at 22°, treated with NIS (90 mg, 0.4 mmol), and stirred for 30 min (the mixture became homogeneous after ca. 5 min and then turbid again). After evaporation, the residue was partitioned between  $\text{H}_2\text{O}$  and AcOEt. The aq. layer was extracted with AcOEt ( $3 \times 15$  ml). The combined org. layers were washed with brine (10 ml), dried ( $\text{MgSO}_4$ ), and evaporated. FC (hexane/AcOEt 4 : 1) gave **24** (70 mg, 80%). White solid.  $R_f$  (hexane/AcOEt 4 : 1) 0.52. M.p. 59–60°.  $[\alpha]_D^{25} = -60.8$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3027m, 3015w, 2929m, 2852m, 2190w, 1733s, 1602w, 1246s, 1159w, 1100m, 1046m, 1013m, 971m, 864m.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 4; additionally, 2.08 (s, AcO).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): see Table 4; additionally, 169.33 (s, C=O); 21.23 (q, Me). HR-EI-MS: 337.9612 (11,  $[M - \text{Me}]^+$ ,  $\text{C}_{10}\text{H}_{10}^{128}\text{IO}_5^+$ ; calc. 337.9607), 336.9577 (100,  $[M - \text{Me}]^+$ ,  $\text{C}_{10}\text{H}_{10}^{126}\text{IO}_5^+$ ; calc. 336.9573). Anal. calc. for  $\text{C}_{11}\text{H}_{13}\text{IO}_5$  (352.13): C 37.52, H 3.72; found: C 37.55, H 3.79.

*(Z)-1,5-Anhydro-6-C-chloro-6-deoxy-2,3-O-isopropylidene-β-D-ribo-hex-5-enofuranose (25)*. A suspension of **21** (240 mg, 1.06 mmol) in 5.25% aq. NaOCl (35 ml) was stirred at 22° for 16 h (the mixture became homogeneous within 30 min), diluted with  $\text{H}_2\text{O}$  (10 ml), and extracted with AcOEt ( $3 \times 15$  ml). The combined org. fractions were washed with brine (20 ml), dried ( $\text{MgSO}_4$ ), and evaporated. FC (hexane/AcOEt 2 : 1) gave **25** (208 mg, 90%). White solid.  $R_f$  (hexane/AcOEt 4 : 1) 0.45. M.p. 71–72°.  $[\alpha]_D^{25} = -25.3$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ).  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 4.  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): see Table 4. EI-MS: 203 ( $[M - \text{Me}]^+$ ).



*X-Ray Analysis of 25*<sup>6</sup>). Recrystallisation of **25** in Et<sub>2</sub>O/hexane 4:1 gave crystals suitable for X-ray analysis: C<sub>9</sub>H<sub>11</sub>ClO<sub>4</sub> (218.636); orthorhombic *P*<sub>2</sub><sub>1</sub><sub>2</sub><sub>1</sub>; *a* = 5.55290(10), *b* = 9.2059(2), *c* = 40.4710(10) Å. *V* = 2068.85 Å<sup>3</sup>; *Z* = 8; *D*<sub>calc.</sub> = 1.404 Mg/m<sup>3</sup>. Intensities were measured on an *Enraf-Nonius CAD-4* diffractometer with MoK<sub>α</sub> radiation (graphite monochromator, λ = 0.71073 Å) at 152 K, θ range 0.998–29.575°. Of the 5331 total collected reflections, 5319 independent reflections were observed. *R* = 0.0658, *R*<sub>w</sub> = 0.1654.

(*Z*)-1,5-Anhydro-6,7,8-trideoxy-2,3-O-isopropylidene-8-C-phenyl-β-D-ribo-oct-5-en-7-ynofuranose (**26**). A suspension of **22** (50 mg, 0.15 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (30 mg, 0.56 mmol) and kept at reflux for 4 h. After evaporation, the residue was treated with soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml), and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 4:1) gave **26** (40 mg, 91%). White solid. *R*<sub>f</sub> (cyclohexane/AcOEt 4:1) 0.53. M.p. 74–75°. [α]<sub>D</sub><sup>25</sup> = +13.2 (*c* = 1.0, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3030w, 3013w, 2939w, 2204w, 1950w, 1683m, 1597w, 1491m, 1456w, 1443w, 1384m, 1376m, 1356m, 1316m, 1231s, 1204m, 1158m, 1138s, 1091s, 1056m, 971m, 925s, 865m. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): see Table 4; additionally, 7.45–7.26 (*m*, 5 arom. H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): see Table 4; additionally, 131.35 (*d*); 128.13 (*2d*); 127.96 (*2d*); 123.26 (*s*). HR-MALDI-MS: 307.0950 ([*M* + Na]<sup>+</sup>, C<sub>17</sub>H<sub>16</sub>NaO<sub>4</sub><sup>+</sup>; calc. 307.0941). Anal. calc. for C<sub>17</sub>H<sub>16</sub>O<sub>4</sub> (284.31): C 71.96, H 5.81; found: C 71.82, H 5.67.

*X-Ray Analysis of 26*<sup>6</sup>). Recrystallisation of **26** in Et<sub>2</sub>O/hexane 4:1 gave crystals suitable for X-ray analysis: C<sub>17</sub>H<sub>16</sub>O<sub>4</sub> (284.311); orthorhombic *P*<sub>2</sub><sub>1</sub><sub>2</sub><sub>1</sub>; *a* = 5.5724(2), *b* = 16.1789(5), *c* = 16.5834(5) Å. *V* = 1495.08 Å<sup>3</sup>; *Z* = 4; *D*<sub>calc.</sub> = 1.263 Mg/m<sup>3</sup>. Intensities were measured on an *Enraf-Nonius CAD-4* diffractometer with MoK<sub>α</sub> radiation (graphite monochromator, λ = 0.71073 Å) at 202 K, θ range 0.998–31.507°. Of the 4757 total collected reflections, 4738 independent reflections were observed. *R* = 0.0616, *R*<sub>w</sub> = 0.1552.

(*Z*)-1,5-Anhydro-6-C-bromo-6-deoxy-2,3-O-isopropylidene-β-D-ribo-hex-5-enofuranose (**27**). A suspension of **23** (100 mg, 0.33 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (30 mg, 0.56 mmol), stirred at 22° overnight, and evaporated. The residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml) and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/AcOEt 4:1) gave **27** (72 mg, 84%). White solid. *R*<sub>f</sub> (hexane/AcOEt 4:1) 0.55. M.p. 118–119°. [α]<sub>D</sub><sup>25</sup> = –34.9 (*c* = 1.0, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3105w, 3029m, 2993m, 2941m, 1692m, 1457m, 1384s, 1376s, 1340m, 1284s, 1233s, 1204s, 1158m, 1122s, 1090s, 1048s, 971s, 927s, 865m, 830m. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 4. <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 4. Anal. calc. for C<sub>9</sub>H<sub>11</sub>BrO<sub>4</sub> (263.09): C 41.09, H 4.21; found: C 41.31, H 4.13.

*X-Ray Analysis of 27*<sup>6</sup>). Recrystallisation of **27** in Et<sub>2</sub>O/hexane 4:1 gave crystals suitable for X-ray analysis: C<sub>9</sub>H<sub>11</sub>BrO<sub>4</sub> (263.092); orthorhombic *P*<sub>2</sub><sub>1</sub><sub>2</sub><sub>1</sub>; *a* = 5.6059(2), *b* = 9.3515(3), *c* = 19.8996(7) Å. *V* = 1043.21 Å<sup>3</sup>; *Z* = 4; *D*<sub>calc.</sub> = 1.675 Mg/m<sup>3</sup>. Intensities were measured on an *Enraf-Nonius CAD-4* diffractometer with MoK<sub>α</sub> radiation (graphite monochromator, λ = 0.71073 Å) at 298 K, θ range 0.998–26.733°. Of the 2064 total collected reflections, 2051 independent reflections were observed. *R* = 0.0556, *R*<sub>w</sub> = 0.1828.

(*Z*)-1,5-Anhydro-6-deoxy-6-C-iodo-2,3-O-isopropylidene-β-D-ribo-hex-5-enofuranose (**28**). A suspension of **24** (36 mg, 0.1 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (10 mg, 0.2 mmol), stirred at 22° overnight, and evaporated. The residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml) and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/AcOEt 4:1) gave **28** (28 mg, 91%). White solid. *R*<sub>f</sub> (hexane/AcOEt 4:1) 0.52. M.p. 130–132°. [α]<sub>D</sub><sup>25</sup> = –24.1 (*c* = 0.96, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3095w, 3029w, 3011m, 2983m, 2959m, 1674m, 1457w, 1384m, 1376m, 1340w, 1283m, 1231s, 1228s, 1205s, 1159m, 1113s, 1087s, 1044m, 971m, 927s, 880m, 865s, 829m. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 4. <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 4. HR-EI-MS: 296.0877 (9, [*M* – Me]<sup>+</sup>, C<sub>8</sub>H<sub>8</sub><sup>128</sup>IO<sub>4</sub><sup>+</sup>, calc. 296.0875), 295.0926 (100, [*M* – Me]<sup>+</sup>, C<sub>8</sub>H<sub>8</sub><sup>126</sup>IO<sub>4</sub><sup>+</sup>, calc. 295.0928), 295 ([*M* – Me]<sup>+</sup>). Anal. calc. for C<sub>9</sub>H<sub>11</sub>IO<sub>4</sub> (310.09): C 34.86, H 3.58; found: C 35.00, H 3.66.

*X-Ray Analysis of 28*<sup>6</sup>). Recrystallisation of **28** in Et<sub>2</sub>O/hexane 4:1 gave crystals suitable for X-ray analysis: C<sub>9</sub>H<sub>11</sub>IO<sub>4</sub> (310.087); orthorhombic *P*<sub>2</sub><sub>1</sub><sub>2</sub><sub>1</sub>; *a* = 5.6538(2), *b* = 20.4230(6), *c* = 9.4368(3) Å. *V* = 1089.64 Å<sup>3</sup>; *Z* = 4; *D*<sub>calc.</sub> = 1.890 Mg/m<sup>3</sup>. Intensities were measured on an *Enraf-Nonius CAD-4* diffractometer with MoK<sub>α</sub> radiation (graphite monochromator, λ = 0.71073 Å) at 298 K, θ range 0.998–28.700°. Of the 5274 total collected reflections, 2798 independent reflections were observed. *R* = 0.0386, *R*<sub>w</sub> = 0.1282.

*Phenyl 2,3,6-Tri-O-acetyl-4-deoxy-4-C-(4-phenylbuta-1,3-dien-1-yl)-1-thio-β-D-glucopyranoside (30)*. A suspension of [Pd<sub>2</sub>(dba)<sub>3</sub>] (6 mg, 0.0125 mmol), CuI (2 mg, 0.01 mmol), P(fur)<sub>3</sub> (6 mg, 0.0125 mmol), **29** [44] (253 mg, 0.5 mmol), and (bromoethynyl)benzene (91 mg, 0.5 mmol) in DMF (3 ml) was degassed twice and stirred for 5 min at 22°. The mixture was treated with Et<sub>3</sub>N (0.3 ml) and stirred for 12 h at 22°. The soln. was diluted with Et<sub>2</sub>O (10 ml), treated with H<sub>2</sub>O (10 ml), and 0.1M aq. HCl (3 ml). The org. layer was washed with H<sub>2</sub>O (2 × 15 ml), and the aq. layer was extracted with Et<sub>2</sub>O (4 × 10 ml). The combined org. fractions were dried

(MgSO<sub>4</sub>) and evaporated. FC (hexane/AcOEt 4:1) gave **30** (246 mg, 82%). White solid. *R<sub>f</sub>* (hexane/AcOEt 4:1) 0.46. M.p. 128–129°. [ $\alpha$ ]<sub>D</sub><sup>25</sup> = –10.7 (*c* = 1.0, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3029<sub>w</sub>, 3014<sub>w</sub>, 2953<sub>w</sub>, 2336<sub>w</sub>, 1751<sub>s</sub>, 1600<sub>w</sub>, 1491<sub>w</sub>, 1479<sub>w</sub>, 1441<sub>w</sub>, 1372<sub>w</sub>, 1231<sub>s</sub>, 1227<sub>s</sub>, 1051<sub>m</sub>, 909<sub>m</sub>. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 7.50–7.26 (*m*, 10 arom. H); 2.11 (*s*, AcO); 2.09 (*s*, 2 AcO). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 170.37, 169.63, 169.42 (3<sub>s</sub>, 3 C=O); 140.63 (*s*); 133.06 (2*d*); 132.56 (2*d*); 129.37 (*d*); 128.83 (2*d*); 128.35 (2*d*); 128.30 (*d*); 121.05 (*s*); 20.94 (*q*, 2 Me); 20.82 (*q*, Me). HR-MALDI-MS: 529.1297 ([*M* + Na]<sup>+</sup>, C<sub>28</sub>H<sub>26</sub>NaO<sub>7</sub>S<sup>+</sup>; calc. 529.1291). Anal. calc. for C<sub>28</sub>H<sub>26</sub>O<sub>7</sub>S (506.58): C 66.21, H 5.26; found: C 66.39, H 5.17.

Table 5. Selected <sup>1</sup>H- and <sup>13</sup>C-NMR Chemical Shifts [ppm], and Coupling Constants [Hz] of the 1-Thio-β-D-glucopyranosides **30–37** in CDCl<sub>3</sub>

	<b>30</b>	<b>31</b>	<b>32</b>	<b>33</b>	<b>34</b>	<b>35</b>	<b>36</b>	<b>37</b>
H–C(1)	4.71	4.69	4.68	4.68	4.67	4.66	4.65	4.65
H–C(2)	4.84	4.81	4.79	4.80	3.35	3.33	3.33	3.33
H–C(3)	5.27	5.22	5.21	5.22	3.87	3.84	3.84	3.86
H–C(4)	2.97	2.79	2.78	2.91	2.67	2.61	2.56	2.54
H–C(5)	3.78	3.72	3.72	3.73	3.80	3.79	3.77	3.79
H <sub>a</sub> –C(6)	4.52	4.47	4.46	4.46	4.42	4.39	4.38	4.39
H <sub>b</sub> –C(6)	4.29	4.24	4.22	4.24	4.06	4.01	4.01	4.03
H–C(2')	–	–	–	–	5.15	5.44	5.38	5.16
HO–C(2)	–	–	–	–	2.80	2.76	2.82	2.70
HO–C(3)	–	–	–	–	2.67	2.61	2.67	2.58
<i>J</i> (1,2)	9.9	9.9	9.9	9.9	9.6	9.9	9.6	9.6
<i>J</i> (2,3)	9.0	9.0	9.0	9.0	8.7	8.5	8.1	8.1
<i>J</i> (3,4)	10.8	10.8	10.8	11.1	10.8	10.5	10.7	10.5
<i>J</i> (4,5)	10.5	10.5	10.5	10.4	10.8	10.5	10.7	10.5
<i>J</i> (4,2')	–	–	–	–	2.1	2.4	2.1	2.1
<i>J</i> (5,6a)	2.2	2.1	2.1	2.2	6.6	6.7	6.9	6.7
<i>J</i> (5,6b)	5.4	5.7	5.7	5.7	9.6	9.6	9.6	9.7
<i>J</i> (6a,6b)	12.0	12.0	12.0	12.0	8.0	7.8	7.8	7.8
<i>J</i> (2,OH)	–	–	–	–	≤ 2.0	2.4	2.7	2.4
<i>J</i> (3,OH)	–	–	–	–	≤ 2.0	≤ 2.0	3.0	2.4
C(1)	85.86	85.82	85.78	–	90.68	89.06	90.91	90.63
C(2)	70.22	70.16	70.17	–	73.54	73.55	73.77	73.60
C(3)	73.28	73.41	73.36	–	74.47	74.29	74.54	74.28
C(4)	36.97	36.28	37.05	–	49.34	48.99	49.80	49.90
C(5)	76.50	76.53	76.42	–	76.88	77.17	75.77	77.50
C(6)	64.11	64.06	64.05	–	69.87	69.60	69.86	69.61
C(1')	<sup>a)</sup>	73.41	73.87	–	161.98	152.31	154.31	157.83
C(2')	69.71	63.28	44.81	–	79.83	90.66	77.49	43.56
C(3')	73.06	–	–	–	83.64	–	–	–
C(4')	76.25	–	–	–	91.97	–	–	–

<sup>a)</sup> Hidden by the signals of CDCl<sub>3</sub>.

*Phenyl 2,3,6-Tri-O-acetyl-4-C-(2-chloroethyl)-4-deoxy-1-thio-β-D-glucopyranoside (31)*. A suspension of **29** (101 mg, 0.25 mmol) in THF (3 ml) was cooled to –78°, treated with 1.6M BuLi in hexane (0.2 ml, 0.3 mmol), and stirred for 3 min. The mixture was transferred *via* a cannula to a stirred, cooled (–78°) soln. of NCS (34 mg, 0.32 mmol) in THF (3 ml). The resulting mixture was slowly warmed to ambient temp., when TLC showed complete conversion. After addition of sat. aq. NH<sub>4</sub>Cl soln. (5 ml), the aq. layer was extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 4:1) gave **31** (70 mg, 64%). White solid. *R<sub>f</sub>* (hexane/AcOEt 4:1) 0.62. M.p. 123–124°. [ $\alpha$ ]<sub>D</sub><sup>25</sup> = –28.5 (*c* = 1.05, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3030<sub>w</sub>, 3009<sub>w</sub>, 2957<sub>w</sub>, 2873<sub>w</sub>, 2245<sub>w</sub>, 1752<sub>s</sub>, 1584<sub>w</sub>,

1479w, 1440w, 1372m, 1234s, 1227s, 1050s, 954w, 913w, 830w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 7.49–7.28 (m, 5 arom. H); 2.10, 2.08, 2.07 (3s, 3 AcO). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 170.36, 169.61, 169.40 (3s, 3 C=O); 132.93 (2d); 131.70 (s); 128.81 (2d); 128.23 (d); 20.92 (q, 2 Me); 20.76 (q, Me). HR-MALDI-MS: 465.0551 (32, [M + Na]<sup>+</sup>, C<sub>20</sub>H<sub>21</sub><sup>37</sup>ClNaO<sub>7</sub>S<sup>+</sup>; calc. 465.0565), 463.0591 (100, [M + Na]<sup>+</sup>, C<sub>20</sub>H<sub>21</sub><sup>35</sup>ClNaO<sub>7</sub>S<sup>+</sup>, calc. 463.0594). Anal. calc. for C<sub>20</sub>H<sub>21</sub>ClO<sub>7</sub>S (440.90): C 54.48, H 4.80; found: C 54.51, H 5.05.

*Phenyl 2,3,6-Tri-O-acetyl-4-C-(2-bromoethynyl)-4-deoxy-1-thio-β-D-glucopyranoside (32)*. A suspension of **29** (101 mg, 0.25 mmol) and NBS (60 mg, 0.336 mmol) in acetone (3 ml) was treated with AgNO<sub>3</sub> (6 mg, 0.036 mmol) and stirred for 30 min at 22°. After evaporation, the residue was partitioned between H<sub>2</sub>O and AcOEt. The aq. layer was extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/AcOEt 4 : 1) gave **32** (101 mg, 83%). White solid. *R*<sub>f</sub> (hexane/AcOEt 4 : 1) 0.58. M.p. 84–85°. [ $\alpha$ ]<sub>D</sub><sup>25</sup> = –28.8 (c = 1.04, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3029m, 3013m, 2955w, 2871w, 2220w, 1753s, 1584w, 1479w, 1440w, 1372m, 1231s, 1081m, 1050s, 954w, 911m, 828w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 7.47–7.26 (m, 5 arom. H); 2.08, 2.06, 2.04 (3s, 3 AcO). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 170.34, 169.56, 169.38 (3s, 3 C=O); 132.91 (2d); 131.70 (s); 128.79 (2d); 128.21 (d); 20.92 (q, 2 Me); 20.74 (q, Me). HR-MALDI-MS: 509.0068 (97, [M + Na]<sup>+</sup>, C<sub>20</sub>H<sub>21</sub><sup>81</sup>BrNaO<sub>7</sub>S<sup>+</sup>; calc. 509.0069), 507.0090 (100, [M + Na]<sup>+</sup>, C<sub>20</sub>H<sub>21</sub><sup>79</sup>BrNaO<sub>7</sub>S<sup>+</sup>; calc. 507.0089). Anal. calc. for C<sub>20</sub>H<sub>21</sub>BrO<sub>7</sub>S (485.35): C 49.49, H 4.36; found: C 49.64, H 4.34.

*Phenyl 2,3,6-Tri-O-acetyl-4-deoxy-4-C-(2-iodoethynyl)-1-thio-β-D-glucopyranoside (33)*. A soln. of AgNO<sub>3</sub> (65 mg, 0.38 mmol) in H<sub>2</sub>O (3 ml) was treated with dil. NH<sub>3</sub>/H<sub>2</sub>O (1 drop), dropwise with a suspension of **29** (101 mg, 0.25 mmol) in acetone (3 ml), NIS (90 mg, 0.4 mmol), and stirred for 30 min (the mixture became homogeneous after ca. 5 min and then became turbid again). After evaporation, the residue was partitioned between H<sub>2</sub>O and AcOEt. The aq. layers were extracted with AcOEt (3 × 15 ml). The combined org. layers were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/AcOEt 4 : 1) gave **33** (109 mg, 73%). White solid. *R*<sub>f</sub> (hexane/AcOEt 4 : 1) 0.62. M.p. 123–124°. [ $\alpha$ ]<sub>D</sub><sup>25</sup> = –121.6 (c = 1.04, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3030m, 3011m, 2957w, 2872w, 2118w, 1953w, 1752s, 1584w, 1479m, 1440m, 1372s, 1240s, 1081s, 1051s, 953w, 913m, 868w, 826w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 7.48–7.27 (m, 5 arom. H); 2.09, 2.08, 2.06 (3s, 3 AcO). HR-MALDI-MS: 555.9987 (22, [M + Na]<sup>+</sup>, C<sub>20</sub>H<sub>21</sub><sup>127</sup>INaO<sub>7</sub>S<sup>+</sup>; calc. 555.9984), 554.9951 (100, [M + Na]<sup>+</sup>, C<sub>20</sub>H<sub>21</sub><sup>126</sup>INaO<sub>7</sub>S<sup>+</sup>; calc. 554.9950).

*Phenyl (Z)-4<sup>i</sup>,6-Anhydro-4-deoxy-4-C-(4-phenyl-1-hydroxybut-1-en-3-yn-1-yl)-1-thio-β-D-glucopyranoside (34)*. A suspension of **30** (51 mg, 0.1 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol) and kept at reflux for 4 h. After evaporation, the residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml) and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/AcOEt 4 : 1) gave **34** (29 mg, 76%). *R*<sub>f</sub> (hexane/AcOEt 4 : 1) 0.40. [ $\alpha$ ]<sub>D</sub><sup>25</sup> = –114.9 (c = 1.02, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3586w, 3500–3150w (br.), 3064w, 3029w, 3012m, 2901w, 2199w, 1669m, 1596w, 1490m, 1480m, 1441m, 1360m, 1303w, 1247m, 1177m, 1130m, 1109m, 1089m, 1070m, 1044m, 1008s, 914w, 862w, 825w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 7.56–7.25 (m, 10 arom. H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 133.04 (2d); 131.23 (2d); 130.80 (s); 129.15 (2d); 128.62 (d); 128.01 (2d); 127.51 (d); 123.76 (s). HR-MALDI-MS: 403.0973 ([M + Na]<sup>+</sup>, C<sub>22</sub>H<sub>20</sub>NaO<sub>4</sub>S<sup>+</sup>; calc. 403.0975). Anal. calc. for C<sub>22</sub>H<sub>20</sub>O<sub>4</sub>S (380.46): C 69.45, H 5.30; found: C 69.53, H 5.50.

*Phenyl (Z)-4<sup>i</sup>,6-Anhydro-4-C-(2-chloro-1-hydroxyethenyl)-4-deoxy-1-thio-β-D-glucopyranoside (35)*. A suspension of **31** (44 mg, 0.1 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol) and kept at reflux for 4 h. After evaporation, the residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml), and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 2 : 1) gave **35** (20 mg, 63%). White solid. *R*<sub>f</sub> (cyclohexane/AcOEt 2 : 1) 0.52. M.p. 85–86°. [ $\alpha$ ]<sub>D</sub><sup>25</sup> = –158.8 (c = 1.0, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3586m, 3391w (br.), 3113w, 3028w, 3008m, 2960s, 2928s, 2901m, 2873s, 1690w, 1650w, 1583w, 1481m, 1441m, 1383m, 1354m, 1308m, 1284w, 1175m, 1131s, 1110s, 1090m, 1071m, 1034s, 1004s, 893m, 826w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 7.55–7.33 (m, 5 arom. H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 5; additionally, 133.02 (2d); 130.71 (s); 129.16 (d); 128.67 (2d). HR-MALDI-MS: 339.0246 (32, [M + Na]<sup>+</sup>, C<sub>14</sub>H<sub>15</sub><sup>37</sup>ClNaO<sub>4</sub>S<sup>+</sup>; calc. 339.0248), 337.0280 (100, [M + Na]<sup>+</sup>, C<sub>14</sub>H<sub>15</sub><sup>35</sup>ClNaO<sub>4</sub>S<sup>+</sup>; calc. 337.0277). Anal. calc. for C<sub>14</sub>H<sub>15</sub>ClO<sub>4</sub>S (398.86): C 54.20, H 4.80; found: C 54.16, H 4.82.

*Phenyl (Z)-4<sup>i</sup>,6-Anhydro-4-C-(2-bromo-1-hydroxyethenyl)-4-deoxy-1-thio-β-D-glucopyranoside (36)*. A suspension of **32** (48 mg, 0.1 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol) and kept at reflux for 4 h. After evaporation, the residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml) and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with

brine (10 ml), dried ( $\text{MgSO}_4$ ), and evaporated. FC (cyclohexane/AcOEt 2:1) gave **36** (27 mg, 74%).  $R_f$  (cyclohexane/AcOEt 2:1) 0.46.  $[\alpha]_D^{25} = -93.6$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3524w (br.), 3450w (br.), 3029s, 2986s, 2941m, 2907m, 2875m, 1732s, 1573w, 1478w, 1465s, 1446s, 1374s, 1251s, 1197m, 1158m, 1096s, 1046s, 1004m, 940m, 918m, 847m.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 5; additionally, 7.54–7.26 (m, 5 arom. H).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): see Table 5; additionally, 133.37 (2d); 131.06 (s); 129.52 (2d); 129.02 (d). HR-MALDI-MS: 382.9758 (97,  $[M + \text{Na}]^+$ ,  $\text{C}_{14}\text{H}_{15}^{81}\text{BrNaO}_4\text{S}^+$ ; calc. 382.9752), 380.9776 (100,  $[M + \text{Na}]^+$ ,  $\text{C}_{14}\text{H}_{15}^{79}\text{BrNaO}_4\text{S}^+$ ; calc. 380.9772). Anal. calc. for  $\text{C}_{14}\text{H}_{15}\text{BrO}_4\text{S}$  (359.24): C 46.81, H 4.21; found: C 46.85, H 4.36.

*Phenyl (Z)-4',6-Anhydro-4-deoxy-4-C-(1-hydroxy-2-iodoethyl)-1-thio- $\beta$ -D-glucopyranoside (37)*. A suspension of **33** (53 mg, 0.1 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol) and kept at reflux for 4 h. After evaporation, the residue was treated with a soln. of 0.1M HCl (0.5 ml) in  $\text{H}_2\text{O}$  (10 ml), and extracted with AcOEt (3  $\times$  15 ml). The combined org. fractions were washed with brine (10 ml), dried ( $\text{MgSO}_4$ ), and evaporated. FC (cyclohexane/AcOEt 2:1) gave **37** (26 mg, 64%)  $R_f$  (cyclohexane/AcOEt 2:1) 0.45. M.p. 66–67°.  $[\alpha]_D^{25} = -99.7$  ( $c = 0.98$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3587w (br.), 3416w (br.), 3027w, 2984m, 1731s, 1478w, 1441w, 1375s, 1249s, 1110m, 1046s, 940w, 846w.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 5; additionally, 7.54–7.32 (m, 5 arom. H).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): see Table 5; additionally, 133.03 (2d); 130.69 (s); 129.16 (2d); 128.66 (d). HR-ESI-MS: 429.9687 (16,  $[M + \text{Na}]^+$ ,  $\text{C}_{14}\text{H}_{15}^{127}\text{INaO}_4\text{S}^+$ ; calc. 429.9689), 428.9625 (100,  $[M + \text{Na}]^+$ ,  $\text{C}_{14}\text{H}_{15}^{126}\text{INaO}_4\text{S}^+$ ; calc. 428.9628).

*Phenyl 6-O-Acetyl-2,3-di-O-benzyl-4-deoxy-4-C-(4-phenylbuta-1,3-diyne-1-yl)-1-thio- $\alpha$ -D-glucopyranoside (39)*. A suspension of  $[\text{Pd}_2(\text{dba})_3]$  (6 mg, 0.0125 mmol), CuI (2 mg, 0.01 mmol), P(fur)<sub>3</sub> (6 mg, 0.0125 mmol), **38** [30] (251 mg, 0.5 mmol) and (bromoethynyl)benzene (91 mg, 0.5 mmol) in DMF (3 ml) was degassed twice and stirred at 22° for 5 min. The mixture was treated with  $\text{Et}_3\text{N}$  (0.3 ml) and stirred for 12 h at 22°. The soln. was diluted with  $\text{Et}_2\text{O}$  (10 ml), and treated with  $\text{H}_2\text{O}$  (10 ml) and 0.1M aq. HCl (3 ml). The org. layer was washed with  $\text{H}_2\text{O}$  (2  $\times$  15 ml), and the aq. layer was extracted with  $\text{Et}_2\text{O}$  (4  $\times$  10 ml). The combined org. fractions were dried ( $\text{MgSO}_4$ ) and evaporated. FC (hexane/AcOEt 4:1) gave **39** (246 mg, 82%). Pale yellow solid.  $R_f$  (hexane/AcOEt 4:1) 0.48. M.p. 126–128°.  $[\alpha]_D^{25} = -149.6$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3066w, 3032m, 3012m, 2245w, 2144w, 1951w, 1880w, 1741s, 1584w, 1491m, 1481m, 1454m, 1441m, 1368m, 1239s, 1206w, 1126s, 1087s, 1038s, 1028s, 910w.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 6; additionally, 7.53–7.26 (m, 20 arom. H); 4.95 (s,  $\text{PhCH}_2$ ); 4.78, 4.72 (2d,  $J = 11.7$ ,  $\text{PhCH}_2$ ); 2.02 (s, AcO).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ ): see Table 6; additionally, 170.48 (s, C=O); 137.93, 137.43, 133.56 (3s); 132.54 (2d); 131.67 (2d); 127.33–129.20 (several d); 121.40 (s); 76.61, 72.62 (2t, 2  $\text{PhCH}_2$ ); 20.90 (q, Me). MALDI-MS: 625 ( $[M + \text{Na}]^+$ ). HR-MALDI-MS: 625.2012 ( $[M + \text{Na}]^+$ ,  $\text{C}_{38}\text{H}_{34}\text{NaO}_5\text{S}^+$ ; calc. 625.2019). Anal. calc. for  $\text{C}_{38}\text{H}_{34}\text{O}_5\text{S}$  (602.75): C 75.72, H 5.69; found: C 75.94, H 5.96.

*Treatment of 39 with MeONa*. A suspension of **39** (60 mg, 0.1 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol) and kept at reflux for 4 h. After evaporation, the residue was treated with a soln. of 0.1M HCl (0.5 ml) in  $\text{H}_2\text{O}$  (10 ml), and extracted with AcOEt (3  $\times$  15 ml). The combined org. fractions were washed with brine (10 ml), dried ( $\text{MgSO}_4$ ), and evaporated. FC (hexane/AcOEt 4:1) gave **41** (28 mg, 51%) and **40** (17 mg, 30%).

*Data of Phenyl (Z)-4',6-Anhydro-2,3-di-O-benzyl-4-deoxy-4-C-(1-hydroxy-4-phenylbut-1-en-3-yn-1-yl)-1-thio- $\alpha$ -D-galactopyranoside (40)*.  $R_f$  (hexane/AcOEt 4:1) 0.52.  $[\alpha]_D^{25} = +11.8$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3066w, 3030m, 3014s, 2930w, 2195w, 1951w, 1879w, 1807w, 1648s, 1596m, 1584m, 1489m, 1481m, 1454m, 1440w, 1354w, 1293w, 1262m, 1172s, 1091s, 1047s, 1027s, 999m, 987m, 931w, 911w, 872w, 842w, 820w.  $^1\text{H-NMR}$  (500 MHz,  $\text{C}_6\text{D}_6$ ): see Table 6; additionally, 7.52–7.46 (m, 2 arom. H); 7.42–7.34 (m, 2 arom. H); 7.29–7.24 (m, 4 arom. H); 7.16–7.01 (m, 8 arom. H); 6.99–6.82 (m, 4 arom. H); 4.51, 4.46 (2d,  $J = 11.7$ ,  $\text{PhCH}_2$ ); 4.34, 4.29 (2d,  $J = 11.4$ ,  $\text{PhCH}_2$ ); 4.18 (t,  $J \approx 3.0$ , irradi. at 4.01  $\rightarrow$  NOE of 3.9%, H–C(5)); 4.11 (dd,  $J = 10.0$ , 4.8, irradi. at 5.98  $\rightarrow$  NOE of 2.4%, H–C(2)); 3.42 (dd,  $J = 10.1$ , 2.5, irradi. at 4.18  $\rightarrow$  NOE of 3.8%, H–C(6)); 2.72 (dt,  $J \approx 5.6$ , 3.4, irradi. at 5.98  $\rightarrow$  NOE of 2.6%, irradi. at 4.18  $\rightarrow$  NOE of 7.4%, irradi. at 4.01  $\rightarrow$  NOE of 12%, H–C(4)).  $^{13}\text{C-NMR}$  (125 MHz,  $\text{C}_6\text{D}_6$ ): see Table 6; additionally, 138.59 (2s); 135.35 (s); 131.46 (2d); 130.67 (2d); 129.16 (2d); 126.86–128.63 (several d); 125.33 (s); 73.23, 72.77 (2t, 2  $\text{PhCH}_2$ ). MALDI-MS: 583 ( $[M + \text{Na}]^+$ ). HR-MALDI-MS: 583.1920 ( $[M + \text{Na}]^+$ ,  $\text{C}_{36}\text{H}_{32}\text{NaO}_4\text{S}^+$ ; calc. 583.1914).

*Data of Phenyl (E)-4',6-Anhydro-2,3-di-O-benzyl-4-deoxy-4-C-(1-hydroxy-4-phenylbut-1-en-3-yn-1-yl)-1-thio- $\alpha$ -D-galactopyranoside (41)*.  $R_f$  (hexane/AcOEt 4:1) 0.62.  $[\alpha]_D^{25} = +37.3$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 3066w, 3033w, 3013s, 2930m, 2893w, 2196w, 1950w, 1878w, 1807w, 1731w, 1648m, 1595w, 1584w, 1489m, 1481m, 1454m, 1440w, 1377m, 1350w, 1307m, 1262m, 1173m, 1101s, 1067m, 1047s, 1027s, 999m, 987m, 931w.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): see Table 6; additionally, 7.54–7.19 (m, 20 arom. H); 4.93 (ddd,  $J = 7.0$ , 5.9, 3.2, irradi. at 3.68  $\rightarrow$  NOE of 10.5%, H–C(5)); 4.77 (d,  $J = 12.0$ ), 4.565 (d,  $J = 11.8$ ) ( $\text{PhCH}_2$ ); 4.570 (dd,  $J \approx 5.7$ , 4.2, irradi. at 3.68  $\rightarrow$  NOE of 7.5%, H–C(3)); 4.558 (d,  $J = 11.4$ ), 4.47 (d,  $J = 12.0$ ) ( $\text{PhCH}_2$ ); 4.22 (dd,  $J = 10.0$ , 6.0, irradi. at

Table 6. Selected  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR Chemical Shifts [ppm], and Coupling Constants [Hz] of the 1-Thio- $\beta$ -D-glucopyranosides **39**–**44**

	<b>39</b> CDCl <sub>3</sub>	<b>40</b> <sup>a)</sup> C <sub>6</sub> D <sub>6</sub>	<b>41</b> <sup>a)</sup> CDCl <sub>3</sub>	<b>42</b> CDCl <sub>3</sub>	<b>43</b> CDCl <sub>3</sub>	<b>44</b> (Glc) CDCl <sub>3</sub>	<b>44</b> (Gal)
H–C(1)	5.64	5.65	5.73	5.64	5.60	5.61	5.65
H–C(2)	3.80	4.11	3.64	3.79	3.75	3.76	4.20–4.13
H–C(3)	3.92	4.01	4.57	3.90	3.88	3.89	4.20–4.13
H–C(4)	2.85	2.72	3.68	2.79	2.81	2.81	3.53 <sup>b)</sup>
H–C(5)	4.57	4.18	4.93	4.56	4.35	4.36	4.20–4.13
H <sub>a</sub> –C(6)	4.35	3.91	4.36	4.33	3.87–3.70	3.94–3.84	4.20–4.13
H <sub>b</sub> –C(6)	4.31	3.42	4.22	4.29	3.87–3.70	3.82–3.72	4.11
H–C(2')	–	5.98	5.34	–	–	–	5.31 <sup>c)</sup>
<i>J</i> (1,2)	5.5	4.8	5.0	5.4	5.1	5.4	4.0
<i>J</i> (2,3)	9.3	10.0	4.2	9.3	9.3	9.3	<sup>d)</sup>
<i>J</i> (3,4)	9.9	5.6	5.7	9.9	9.9	9.7	<sup>d)</sup>
<i>J</i> (4,5)	10.8	3.4	7.0	10.5	10.5	10.5	<sup>d)</sup>
<i>J</i> (4,2')	–	2.2	1.9	–	–	–	1.5
<i>J</i> (5,6a)	4.2	0	3.1	3.6	2.1	3.0	<sup>d)</sup>
<i>J</i> (5,6b)	3.6	2.5	6.0	2.4	4.8	5.4	2.7
<i>J</i> (6a,6b)	11.1	10.1	10.0	10.8	<sup>d)</sup>	<sup>d)</sup>	10.0
C(1)	86.99	87.29	85.31	86.90	87.10		
C(2)	79.52 <sup>e)</sup>	76.76	74.14	79.33 <sup>e)</sup>	79.54 <sup>e)</sup>		
C(3)	79.40 <sup>e)</sup>	75.10	71.60	78.99 <sup>e)</sup>	79.03 <sup>e)</sup>		
C(4)	38.20	46.11	43.46	37.86	37.39		
C(5)	69.34	72.13	70.21	69.24	71.66		
C(6)	64.32	74.27	75.19	64.21	62.94		
C(1')	79.03	164.23	168.59	74.82	75.10		
C(2')	68.94	81.61	80.85	68.49	68.35		
C(3')	73.67	86.70	87.00	–	–		
C(4')	76.16	92.64	92.30	–	–		

<sup>a)</sup> Assignment based on selective homodecoupling experiments, and a HSQC and a HMBC spectrum.

<sup>b)</sup> *J*(2',H–C(4) of Glc) = 1.5 Hz. <sup>c)</sup> Br. s;  $w_{1/2}$  = 8.7 Hz. <sup>d)</sup> Not assigned. <sup>e)</sup> Assignments may be interchanged.

4.93 → NOE of 3.5%, H'–C(6)); 3.68 (*ddd*,  $J \approx 7.2, 5.6, 1.8$ , irradiated at 4.93 → NOE of 9%, H–C(4)); no NOE observed upon irradiation at 5.34.  $^{13}\text{C}$ -NMR (75 MHz, CDCl<sub>3</sub>): see Table 6; additionally, 137.73, 137.02, 135.74 (3s); 130.65 (2d), 130.09 (2d); 128.95–126.50 (several d); 124.13 (s); 74.37, 73.73 (2t, 2 PhCH<sub>2</sub>). MALDI-MS: 583 ([*M* + Na]<sup>+</sup>). HR-MALDI-MS: 583.1919 ([*M* + Na]<sup>+</sup>, C<sub>36</sub>H<sub>52</sub>NaO<sub>4</sub>S<sup>+</sup>; calc. 583.1914).

4,4'-(Buta-1,3-diyne-1,4-diyl)bis(phenyl 6-O-Acetyl-2,3-di-O-benzyl-4-deoxy-1-thio- $\alpha$ -D-glucopyranoside) (**42**). Under Ar, a soln. of Cu(OAc)<sub>2</sub> (6.7 g, 36.88 mmol) in pyridine (72 ml) was stirred at 60° for 3 h, treated with a soln. of **38** (900 mg, 1.84 mmol) in pyridine (10 ml), stirred for 1 h, cooled to r.t., and evaporated. Pyridine was removed by two co-distillations with toluene. FC (hexane/AcOEt 5:1 → 1:1) gave **42** (795 mg, 88%). *R<sub>f</sub>* (hexane/AcOEt 1:1) 0.38.  $^1\text{H}$ -NMR (75 MHz, CDCl<sub>3</sub>): see Table 6; additionally, 7.50–7.24 (*m*, 15 arom. H); 4.93 (*d*,  $J = 10.8$ ), 4.88 (*d*,  $J = 10.5$ ), 4.77 (*d*,  $J = 12.0$ ), 4.71 (*d*,  $J = 11.7$ ) (4 PhCH); 2.01 (*s*, AcO).  $^{13}\text{C}$ -NMR (75 MHz, CDCl<sub>3</sub>): see Table 6; additionally, 170.40 (*s*, C=O); 137.86, 137.38 (2s); 133.48 (*s*); 131.66 (2d); 128.91 (2d); 128.40 (2d); 128.30 (2d); 128.14 (2d); 127.98 (2d); 127.93, 127.76, 127.31 (3d); 76.11, 72.57 (2t, 2 PhCH<sub>2</sub>); 20.87 (*q*, Me). MALDI-MS: 1025 ([*M* + Na]<sup>+</sup>).

4,4'-(Buta-1,3-diyne-1,4-diyl)bis(phenyl 2,3-Di-O-benzyl-4-deoxy-1-thio- $\alpha$ -D-glucopyranoside) (**43**). A soln. of **42** (600 mg, 0.6 mmol) in THF/MeOH/H<sub>2</sub>O 4:4:1 (45 ml) was treated with 1*M* MeONa in MeOH (3 ml), heated for 15 min to 60°, cooled to r.t., treated with Amberlite IR-120 (H<sup>+</sup> form), and stirred for 5 min. Filtration, evaporation of the filtrate, and FC (hexane/AcOEt 5:1 → 1:1) gave **43** (549 mg, 99%). *R<sub>f</sub>* (hexane/AcOEt 1:1) 0.47.  $^1\text{H}$ -NMR (75 MHz, CDCl<sub>3</sub>): see Table 6; additionally, 7.49–7.26 (*m*, 15 arom. H); 4.92 (*d*,  $J = 11.1$ ), 4.88 (*d*,  $J = 11.1$ ), 4.77 (*d*,  $J = 11.7$ ), 4.71 (*d*,  $J = 11.7$ ) (4 PhCH); 1.57 (*br. s*, OH).  $^{13}\text{C}$ -NMR (75 MHz,

CDCl<sub>3</sub>): see Table 6; additionally, 137.96, 137.44 (2s); 133.40 (s); 132.03 (2d); 128.98 (2d); 128.37 (2d); 128.26 (2d); 128.09 (2d); 127.98 (2d); 127.89, 127.68, 127.46 (3d); 75.95, 72.66 (2t, 2 PhCH<sub>2</sub>). MALDI-MS: 941 ([M + Na]<sup>+</sup>).

*Treatment of 43 with Na<sub>2</sub>S · 9 H<sub>2</sub>O.* A soln. of **43** (50 mg, 32.6 μmol) in MeOCH<sub>2</sub>CH<sub>2</sub>OH (3 ml) was treated with Na<sub>2</sub>S · 9 H<sub>2</sub>O (8 mg, 32.6 μmol), kept for 30 min at reflux, and cooled to 23°. The suspension was diluted with AcOEt (0.5 ml) and hexane (0.8 ml), stirred for 30 min at 23°, and filtered over *Celite*. Evaporation of the filtrate and FC (hexane/AcOEt 20 : 1 → 10 : 1) gave an unknown 4 : 3 : 2 mixture (5.5 mg, ca. 10%) and **44** (10 mg, 20%).

*Data of Phenyl 2,3-Di-O-benzyl-4-deoxy-4-[(Z)-4-(phenyl 2,3-Di-O-benzyl-4-deoxy-1-thio-α-D-galactopyranosid-4-C,6-O-ylidene)but-3-en-1-yn-1-yl]-1-thio-α-D-glucopyranoside (44).* R<sub>f</sub> (toluene/AcOEt 2 : 1) 0.48. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 6; additionally, 7.55–7.21 (m, 30 arom. H); 4.88 (2d, J = 10.2, PhCH<sub>2</sub>); 4.82–4.70 (m, 6 PhCH); 1.72 (t, J = 6.6, HO–C(6)).

*Data of the 4 : 3 : 2 Mixture.* R<sub>f</sub> (toluene/AcOEt 2 : 1) 0.69. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 5.79 (s, 0.2 H), 5.72 (d, J = 10.2, 0.2 H), 5.68 (d, J = 4.5, 0.8 H), 5.66 (d, J ≈ 4.8, 1.2 H) (2 H–C(1)); 5.18 (d, J = 1.0, 0.4 H); 5.14 (t, J ≈ 1.5, 0.6 H) (1 olef. H); 3.43 (td, J ≈ 6.3, 2.5, 0.4 H), 3.33 (br. t, J = 10.5, 0.2 H), 2.92 (td, J = 10.5, 2.5, 0.6 H) (1.2 H–C(4)).

*Allyl 2,3-Di-O-benzyl-4,6-bis-O-(4-methoxybenzyl)-β-D-galactopyranoside (46).* A soln. of **45** [63] (80 mg, 0.2 mmol) in DMF (5 ml) was cooled to 0° and treated with 60% NaH in mineral oil (26 mg, 0.67 mmol) in small portions. After the evolution of gas had ceased (ca. 30 min), the mixture was treated with 4-methoxybenzyl chloride (0.1 ml, 0.73 mmol) and Bu<sub>4</sub>NI (4 mg, 0.01 mmol), stirred at r.t. for 16 h, diluted with Et<sub>2</sub>O (10 ml), and treated dropwise with H<sub>2</sub>O (5 ml). The layers were separated, and the org. layer was washed with brine, dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 8 : 1) gave **46** (115 mg, 90%). R<sub>f</sub> (cyclohexane/AcOEt 4 : 1) 0.52. [α]<sub>D</sub><sup>25</sup> = –10.5 (c = 1.10, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3020s, 2958m, 2937m, 2912m, 2860m, 2839m, 1884w, 1612s, 1586m, 1513s, 1465m, 1442m, 1421w, 1384w, 1361m, 1302m, 1248s, 1173s, 1110m, 1072m, 1035s, 1011w, 919w, 895w, 825w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 7.40–7.18 (m, 14 arom. H); 6.93–6.78 (m, 4 arom. H); 5.95 (dddd, J = 17.2, 10.5, 6.0, 5.4, CH<sub>2</sub> = CH); 5.33 (dq, J = 17.1, 1.8), 5.18 (dq, J = 10.8, 1.8) (CH<sub>2</sub> = CH); 4.95 (d, J = 11.1), 4.86 (d, J = 11.4), 4.77 (d, J = 10.5), 4.76 (d, J = 12.0), 4.70 (d, J = 12.0), 4.58 (d, J = 11.4), 4.41 (d, J ≈ 11.2), 4.35 (d, J = 11.1) (8 ArCH); 4.41 (ddt, J = 12.9, 5.1, 1.8), 4.12 (ddt, J = 12.9, 6.0, 1.5) (CH<sub>2</sub> = CHCH<sub>2</sub>); 3.81, 3.79 (2s, 2 MeO). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 159.14, 158.95 (2s); 138.63, 138.45 (2s); 134.11 (d, CH<sub>2</sub> = CH); 130.72, 129.90 (2s); 129.84–127.40 (several d); 116.89 (t, CH<sub>2</sub> = CH); 113.74 (2d); 113.45 (2d); 75.25, 73.94, 73.18, 72.99 (4t, 4 ArCH<sub>2</sub>); 70.11 (t, CH<sub>2</sub> = CHCH<sub>2</sub>); 55.30, 55.27 (2q, 2 MeO). MALDI-MS: 663 ([M + Na]<sup>+</sup>). HR-MALDI-MS: 663.2920 ([M + Na]<sup>+</sup>, C<sub>39</sub>H<sub>44</sub>NaO<sub>8</sub>); calc. 663.2928). Anal. calc. for C<sub>39</sub>H<sub>44</sub>O<sub>8</sub> (640.77): C 73.10, H 6.92; found: C 73.11, H 7.05.

*2,3-Di-O-benzyl-4,6-bis-O-(4-methoxybenzyl)-D-galactopyranose (47).* A suspension of [Ir(COD)(PPh<sub>2</sub>-Me)PF<sub>6</sub>]<sub>2</sub> (6 mg, 0.007 mmol) in dry THF (3 ml) was degassed and stirred under H<sub>2</sub> for 10 min at 25° (red suspension turned into yellow soln.). After replacement of H<sub>2</sub> by Ar, the yellow soln. was treated with a soln. of **46** (110 mg, 0.225 mmol) in THF (5 ml), stirred for 1 h, treated with H<sub>2</sub>O (10 ml) and I<sub>2</sub> (114 mg, 0.45 mmol), stirred for 1 h, and treated with chilled 5% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> soln. (10 ml). After evaporation, a soln. of the residue in AcOEt was washed with brine, dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 5 : 1) gave **47** (85 mg, 82%). R<sub>f</sub> (cyclohexane/AcOEt 2 : 1) 0.55. [α]<sub>D</sub><sup>25</sup> = +4.3 (c = 1.10, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3416w (br.), 3021s, 3014s, 2936w, 2914w, 2873w, 2839w, 1612m, 1586w, 1514s, 1465w, 1455w, 1363w, 1302m, 1249s, 1173m, 1154w, 1093s, 1037s, 909m, 827w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>; α-D-**47**/β-D-**47** 55 : 45): 7.49–7.30 (m, 7 arom. H); 7.38–7.19 (m, 7 arom. H); 6.88–6.81 (m, 4 arom. H); 5.29 (t, J ≈ 3.2, addn. of D<sub>2</sub>O → d, J = 3.2, 0.55 H–C(1)); 4.93 (d, J = 10.8, 0.55 H), 4.86 (d, J = 11.4, 0.45 H), 4.85 (d, J = 11.7, 0.55 H), 4.82 (d, J = 12.0, 0.45 H), 4.80 (d, J = 12.0, 0.55 H), 4.77 (d, J = 12.0, 0.45 H), 4.75 (d, J = 10.5, 0.55 H), 4.73 (d, J = 10.5, 0.45 H), 4.71 (d, J = 10.5, 0.55 H), 4.70 (d, J = 11.7, 0.45 H) (5 PhCH); 4.65 (dd, J = 7.5, 6.6, addn. of D<sub>2</sub>O → d, J = 7.5, 0.45 H–C(1)); 4.55 (d, J = 11.4, 0.45 H), 4.53 (d, J = 11.1, 0.55 H), 4.43 (br. d, J = 11.7, 1 H), 4.33 (d, J = 11.7, 0.55 H), 4.32 (d, J = 11.7, 0.45 H) (3 PhCH); 4.15 (t, J ≈ 6.4, 0.55 H–C(5)); 4.03 (dd, J = 9.3, 3.6, 0.55 H–C(2)); 3.93 (br. s, 0.55 H–C(4)); 3.91 (dd, J = 9.3, 2.7, 0.55 H–C(3)); 3.85 (d, J = 3.0, 0.45 H–C(4)); 3.80, 3.795, 3.79 (3s, 2 MeO); 3.765 (dd, J = 9.6, 7.5, 0.45 H–C(2)); 3.760 (d, J = 6.6, exchanged with D<sub>2</sub>O, 0.45 HO–C(1)); 3.60–3.45 (m, 0.45 H–C(5), 1.55 H–C(6)); 3.435 (dd, J = 9.3, 2.5, 0.45 H–C(3)); 3.420 (dd, J = 9.3, 6.9, 0.45 H–C(6)); 3.38 (d, J = 2.4, exchanged with D<sub>2</sub>O, 0.55 HO–C(1)). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>, α-D-**47**/β-D-**47** 55 : 45): signals of α-D-**47**: 159.15, 159.06 (2s); 138.59, 138.20 (2s); 130.62 (s); 129.87 (2d); 129.84 (s); 129.56 (2d); 128.31 (2d); 128.23 (2d); 127.92 (2d); 127.68 (d); 127.48 (d); 127.42 (2d); 113.74 (2d); 113.58 (2d); 91.84 (d, C(1)); 78.80 (d, C(3)); 76.62 (d, C(2)); 74.19 (t, PhCH<sub>2</sub>); 74.17 (d, C(4)); 73.46, 73.12, 72.94 (3t, 3PhCH<sub>2</sub>); 69.52 (d, C(5)); 68.79 (t, C(6)); 55.32 (q, 2 MeO); signals of β-D-**47**: 159.19, 159.06 (2s); 138.54, 138.35 (2s); 130.56 (s); 129.84 (2d);

Table 7. Selected  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR Chemical Shifts [ppm], and Coupling Constants [Hz] of the D-Galactopyranose Derivatives **46** and **48–54** in  $\text{CDCl}_3$ 

	<b>46</b>	<b>48</b>	<b>49</b>	<b>50</b>	<b>51</b>	<b>52<sup>a)</sup></b>	<b>53<sup>a)</sup>b)</b>	<b>54<sup>a)</sup></b>
H–C(1)	4.41	–	4.03	4.01	4.15	4.29	4.24	4.28
H–C(2)	3.87	4.46	3.87	3.87	3.91	3.75–3.73	3.77	3.77
H–C(3)	3.58–3.47	3.86	3.48	3.50	3.51	3.73–3.71	3.75	3.74
H–C(4)	4.62	4.14	4.03	4.04	4.06	4.59	4.60	4.55
H–C(5)	3.86	4.30	3.43	3.45	3.47	3.98	4.00	4.11
H <sub>a</sub> –C(6)	3.58–3.47	3.67	3.95	3.96	3.94	3.79	3.83	4.31
H <sub>b</sub> –C(6)	3.58–3.47	3.61	3.79	3.79	3.80	3.68	3.73	4.20
HO–C(4)	–	–	2.70	2.64	2.73	–	–	–
HO–C(6)	–	–	2.24	2.11	2.28	1.77	1.78	–
H–C(2')	–	–	–	2.54	–	5.21	4.81	4.83
$J(1,2')$	–	–	–	2.1	–	0.9	0.6	≤ 1.0
$J(1,2)$	7.5	–	9.6	9.9	9.6	2.4	2.0	2.0
$J(2,3)$	8.1	9.6	9.0	8.7	9.0	<sup>c)</sup>	≤ 2.0	≤ 2.0
$J(3,4)$	4.2	2.4	3.3	3.0	3.3	1.5	≤ 1.0	≤ 1.0
$J(4,5)$	≤ 1.0	1.2	1.8	1.0	1.2	1.5	≤ 1.0	≤ 1.0
$J(5,6_a)$	1.8	8.1	6.6	6.6	6.6	6.9	6.5	6.3
$J(5,6_b)$	7.8	5.7	4.5	4.5	4.5	7.2	7.2	6.3
$J(6_a,6_b)$	<sup>c)</sup>	9.0	11.7	11.7	11.7	11.4	11.1	11.1
$J(4,\text{OH})$	–	–	1.5	2.0	1.5	–	–	–
$J(5,\text{OH})$	–	–	1.5	1.0	1.0	–	–	–
$J(6_a,\text{OH})$	–	–	4.5	4.8	3.3	4.5	4.5	–
$J(6_b,\text{OH})$	–	–	8.4	8.7	7.5	7.5	7.2	–
C(1)	102.89	169.87	70.30	69.70	70.50	69.56	69.77	69.71
C(2)	79.61	77.43 <sup>d)</sup>	78.47	78.13	78.06 <sup>d)</sup>	80.02	80.10	79.96
C(3)	82.42	80.13	81.29	81.37	81.42	80.35	80.59	80.36
C(4)	73.45	71.96	67.76	67.62	67.60	71.09	71.22	71.54
C(5)	72.84	77.31 <sup>d)</sup>	77.97	77.99	78.03 <sup>d)</sup>	74.84	74.94	72.62
C(6)	68.59	67.17	62.86	62.86	62.79	61.97	62.13	63.45
C(1')	–	–	102.13	80.74	79.08 <sup>e)</sup>	152.33	159.61	159.14
C(2')	–	–	91.11	74.15	70.70	78.37	82.35	82.60
C(3')	–	–	–	–	73.21	–	83.25	83.14
C(4')	–	–	–	–	78.70 <sup>e)</sup>	–	93.47	93.87

<sup>a)</sup> Same numbering as **50** and **51**. <sup>b)</sup> Assignment based on a DQFCOSY, a HSQC, and a HMBC spectrum. <sup>c)</sup> Not assigned. <sup>d)</sup> <sup>e)</sup> Assignments may be interchanged.

129.73 (s); 129.61 (2d); 128.32 (4d); 128.10 (2d); 127.54 (d); 127.52 (d); 127.46 (2d); 113.77 (2d); 113.58 (2d); 97.76 (d, C(1)); 82.25 (d, C(3)); 80.80 (d, C(2)); 75.11, 74.07 (2t, 2 PhCH<sub>2</sub>); 73.62 (d, C(4)); 73.20 (t, PhCH<sub>2</sub>); 73.01 (d, C(5)); 72.94 (t, PhCH<sub>2</sub>); 68.68 (t, C(6)); 55.32 (q, 2 MeO). MALDI-MS: 623 ([M + Na]<sup>+</sup>). HR-MALDI-MS: 623.2614 ([M + Na]<sup>+</sup>, C<sub>36</sub>H<sub>40</sub>NaO<sub>8</sub><sup>+</sup>; calc. 623.2615).

**2,3-Di-O-benzyl-4,6-bis-O-(4-methoxybenzyl)-D-galactono-1,5-lactone (48)**. A suspension of **47** (672 mg, 1.12 mmol) in DMSO (6 ml) was treated with Ac<sub>2</sub>O (3 ml) and stirred for 6 h. The clear yellow soln. was added dropwise to cold stirred H<sub>2</sub>O. After extraction with CH<sub>2</sub>Cl<sub>2</sub>, evaporation and crystallisation from hexane gave **48** (590 mg, 88%). *R*<sub>f</sub> (cyclohexane/AcOEt 5 : 1) 0.45.  $[\alpha]_{\text{D}}^{25} = +151.4$  (*c* = 1.0, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3067w, 3021s, 3014m, 2959w, 2936w, 2914w, 2875w, 2839w, 1748s, 1612m, 1586w, 1514s, 1465m, 1455m, 1442w, 1361m, 1302m, 1249s, 1174m, 1103s, 1061m, 1035s, 910w, 847w, 824w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 7.49–7.30 (m, 10 arom. H); 7.29–7.10 (m, 4 arom. H); 6.91–6.80 (m, 4 arom. H); 5.18 (d, *J* = 11.4), 4.84 (d, *J* = 10.8), 4.78 (d, *J* = 11.1), 4.74 (d, *J* = 12.6), 4.67 (d, *J* = 12.0), 4.54 (d, *J* = 10.8), 4.46 (d, *J* = 11.4), 4.39 (d, *J* = 11.7) (8 PhCH); 3.80, 3.79 (2s, 2 MeO). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 159.29, 159.18 (2s); 137.69, 137.44 (2s); 129.78 (s); 129.60 (2d); 129.56 (2d); 129.36 (s); 128.36 (2d); 128.33 (2d); 128.25 (2d);

127.77 (*d*); 127.68 (*d*); 127.38 (*2d*); 113.80 (*2d*); 113.67 (*2d*); 75.27, 74.30, 73.30, 72.72 (*4t*, 4 PhCH<sub>2</sub>); 55.30 (2 MeO). MALDI-MS: 621 ([*M* + Na]<sup>+</sup>). HR-MALDI-MS: 621.2467 ([*M* + Na]<sup>+</sup>, C<sub>36</sub>H<sub>38</sub>NaO<sub>8</sub>; calc. 621.2459). Anal. calc. for C<sub>36</sub>H<sub>38</sub>O<sub>8</sub> (598.69): C 72.22, H 6.40; found: C 72.23, H 6.51.

*1-(2,3-Di-O-benzyl-β-D-galactopyranosyl)-2-(trimethylsilyl)ethyne (49)*. Under Ar, a stirred and cooled (–78°) soln. of Me<sub>3</sub>SiC≡CH (0.3 ml, 2 mmol) in THF (8 ml) was treated dropwise with 1.6M BuLi in hexane (1.2 ml) over a period of 0.5 h and stirred for 1 h. This soln. was transferred into a cooled (–78°) soln. of **48** (240 mg, 0.4 mmol) in THF (8 ml) over a period of 10 min with a canula. The resulting pale brown soln. was stirred for 4 h at –78°, treated with sat. aq. NH<sub>4</sub>Cl soln. (2 ml), warmed to r.t., stirred for 0.5 h, and worked up (AcOEt). After evaporation, a soln. of the residue (280 mg) in CH<sub>2</sub>Cl<sub>2</sub>/MeCN 1:1 (5 ml) was cooled to –40°, treated with a soln. of BF<sub>3</sub>·Et<sub>2</sub>O (0.3 ml, 2.3 mmol) and Et<sub>3</sub>SiH (0.6 ml, 3.6 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/MeCN 1:1 (5 ml) using a canula over a period of 0.5 h. The mixture was stirred at –40° for 1 h and at –10 to –15° for 16 h, treated with sat. aq. NaHCO<sub>3</sub> soln. (5 ml), stirred for 1 h at –10 to –15°, and worked up (AcOEt). Evaporation and FC (cyclohexane/AcOEt 5:1) gave **49** (101 mg, 63%). Pale yellow oil. *R*<sub>f</sub> (cyclohexane/AcOEt 5:1) 0.42. [*α*]<sub>D</sub><sup>25</sup> = –52.6 (*c* = 1.1, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3577*w* (br.), 3350*w* (br.), 3090*w*, 3067*w*, 3032*w*, 3013*m*, 2961*m*, 2876*m*, 2180*w*, 1951*w*, 1875*w*, 1810*w*, 1732*w*, 1606*w*, 1497*w*, 1454*m*, 1365*m*, 1297*m*, 1251*s*, 1091*s*, 1028*m*, 910*w*, 846*s*. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 7.42–7.28 (*m*, 10 arom. H); 4.99 (*d*, *J* = 10.5), 4.83 (*d*, *J* = 10.5) (PhCH<sub>2</sub>); 4.73 (*s*, PhCH<sub>2</sub>); 0.19 (*s*, Me<sub>3</sub>Si). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 137.95, 137.49 (2*s*); 128.45 (2*d*); 128.25 (2*d*); 128.07 (2*d*); 127.95 (2*d*); 127.72 (2*d*); 75.78, 72.36 (2*t*, 2 PhCH<sub>2</sub>); 0.16 (*q*, Me<sub>3</sub>Si). MALDI-MS: 463 ([*M* + Na]<sup>+</sup>). HR-MALDI-MS: 463.1906 ([*M* + Na]<sup>+</sup>, C<sub>25</sub>H<sub>32</sub>NaO<sub>5</sub>Si<sup>+</sup>; calc. 463.1911).

*2,3-Di-O-benzyl-β-D-galactopyranosyl)ethyne (50)*. A suspension of **49** (88 mg, 0.2 mmol) in dry MeOH (5 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol), kept at reflux for 10 h, and evaporated. The residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml), and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. Crystallisation from *i*-PrOH gave **50** (68 mg, 93%). White solid. M.p. 133–134°. [*α*]<sub>D</sub><sup>25</sup> = –52.6 (*c* = 1.1, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3572*w* (br.), 3307*w*, 3031*w*, 3009*w*, 2929*w*, 2853*w*, 2256*w*, 1603*w*, 1497*w*, 1454*w*, 1374*s*, 1298*w*, 1265*s*, 1249*s*, 1093*s*, 1046*m*, 1002*w*, 941*w*, 918*w*, 846*w*. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 7.40–7.26 (*m*, 10 arom. H); 4.99, 4.84 (2*d*, *J* = 10.5, PhCH<sub>2</sub>); 4.73 (*s*, PhCH<sub>2</sub>). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 137.82, 137.41 (2*s*); 128.48 (2*d*); 128.27 (2*d*); 128.14 (2*d*); 127.99, 127.78 (2*d*); 127.75 (2*d*); 75.81, 72.30 (2*t*, 2 PhCH<sub>2</sub>). MALDI-MS: 391 ([*M* + Na]<sup>+</sup>). HR-MALDI-MS: 391.1521 ([*M* + Na]<sup>+</sup>, C<sub>22</sub>H<sub>24</sub>NaO<sub>5</sub>; calc. 391.1516). Anal. calc. for C<sub>22</sub>H<sub>24</sub>O<sub>5</sub> (368.43): C 71.72, H 6.57; found: C 71.68, H 6.71.

*1-(2,3-Di-O-benzyl-β-D-galactopyranosyl)-4-phenylbuta-1,3-diyne (51)*. A suspension of [Pd<sub>2</sub>(dba)<sub>3</sub>] (6 mg, 0.0125 mmol), CuI (2 mg, 0.01 mmol), P(fur)<sub>3</sub> (6 mg, 0.0125 mmol), **50** (184 mg, 0.5 mmol), and (bromoethynyl)benzene (91 mg, 0.5 mmol) in DMF (3 ml) was degassed twice and stirred at 22° for 5 min. The mixture was treated with Et<sub>3</sub>N (0.3 ml) and stirred for 12 h at 22°. The soln. was diluted with Et<sub>2</sub>O (10 ml), and treated with H<sub>2</sub>O (10 ml) and 0.1M aq. HCl (3 ml). After separation of the layers, the aq. layer was extracted with Et<sub>2</sub>O (4 × 10 ml), and the Et<sub>2</sub>O layer was washed with H<sub>2</sub>O (2 × 15 ml). The combined org. fractions were dried (MgSO<sub>4</sub>) and evaporated. FC (cyclohexane/AcOEt 3:1) gave **51** (198 mg, 85%). *R*<sub>f</sub> (cyclohexane/AcOEt 3:1) 0.47. [*α*]<sub>D</sub><sup>25</sup> = –146.6 (*c* = 1.1, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3581*w* (br.), 3442*w* (br.), 3067*w*, 3032*w*, 3013*m*, 2928*m*, 2876*m*, 2242*w*, 1952*w*, 1881*w*, 1807*w*, 1672*w*, 1597*w*, 1554*w*, 1492*w*, 1454*m*, 1443*w*, 1367*m*, 1291*m*, 1091*s*, 1028*m*, 1013*m*, 985*w*, 914*w*, 884*w*, 834*w*. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 7.75–7.72 (*m*, 1 arom. H); 7.53–7.48 (*m*, 2 arom. H); 7.45–7.40 (*m*, 2 arom. H); 7.40–7.30 (*m*, 8 arom. H); 7.19–7.15 (*m*, 1 arom. H); 6.58–6.54 (*m*, 1 arom. H); 4.98, 4.86 (2*d*, *J* = 10.2, PhCH<sub>2</sub>); 4.74 (*s*, PhCH<sub>2</sub>). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 137.68, 137.41 (2*s*); 132.55 (2*d*); 128.49 (2*d*); 129.33 (*d*); 128.33 (6*d*); 128.02 (*d*); 127.85 (*d*); 127.76 (2*d*); 121.17 (*s*); 75.89, 72.32 (2*t*, 2 PhCH<sub>2</sub>). MALDI-MS: 491 ([*M* + Na]<sup>+</sup>). HR-MALDI-MS: 491.1829 ([*M* + Na]<sup>+</sup>, C<sub>30</sub>H<sub>28</sub>NaO<sub>5</sub>; calc. 491.1829).

*(Z)-2,6:3,7-Dianhydro-4,5-di-O-benzyl-8-bromo-8-deoxy-L-glycero-L-galacto-oct-7-enitol (52)*. A suspension of **50** (92 mg, 0.25 mmol) and NBS (60 mg, 0.336 mmol) in acetone (3 ml) was treated with AgNO<sub>3</sub> (6 mg, 0.036 mmol) and stirred for 30 min at 22°. After evaporation, the residue was partitioned between H<sub>2</sub>O and AcOEt. The aq. layer was extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 4:1) gave **52** (113 mg, 93%). *R*<sub>f</sub> (cyclohexane/AcOEt 2:1) 0.55. [*α*]<sub>D</sub><sup>25</sup> = –156.2 (*c* = 1.02, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3594*w*, 3416*w* (br.), 3107*w*, 3090*w*, 3067*w*, 3031*m*, 3013*m*, 2944*w*, 2885*m*, 1664*m*, 1603*w*, 1496*w*, 1454*m*, 1363*m*, 1265*s*, 1146*s*, 1103*s*, 1038*s*, 1028*s*, 993*m*, 912*w*, 884*w*, 860*w*, 821*w*. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 7.39–7.29 (*m*, 10 arom. H); 4.66, 4.64 (2*d*, *J* = 12.0, 2 PhCH); 4.53 (*d*, *J* = 12.0, 2 PhCH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 137.24, 137.04 (2*s*); 128.45 (2*d*); 128.42 (2*d*); 128.07 (*d*); 128.02 (2*d*); 127.92 (2*d*); 127.82 (*d*);



71.01, 70.47 (2t, 2 PhCH<sub>2</sub>). HR-MALDI-MS: 471.0601 (97, [M + Na]<sup>+</sup>, C<sub>22</sub>H<sub>23</sub>Na<sup>81</sup>BrO<sub>5</sub><sup>+</sup>; calc. 471.0601), 469.0616 (100, [M + Na]<sup>+</sup>, C<sub>22</sub>H<sub>23</sub>Na<sup>79</sup>BrO<sub>5</sub><sup>+</sup>; calc. 469.0621).

(Z)-2,6:3,7-Dianhydro-4,5-di-O-benzyl-8,9,10-trideoxy-10-C-phenyl-L-glycero-L-galacto-dec-7-en-9-ynitol (**53**). A suspension of **51** (47 mg, 0.1 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol), kept at reflux for 10 h, and evaporated. The residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml) and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 4:1) gave **53** (44 mg, 93%). R<sub>f</sub> (cyclohexane/AcOEt 2:1) 0.50. [α]<sub>D</sub><sup>25</sup> = -220.8 (c = 1.05, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3429w (br.), 3066w, 3031m, 3013m, 2929w, 2892w, 2200w, 1951w, 1879w, 1808w, 1779w, 1658m, 1596w, 1490m, 1454m, 1442w, 1381m, 1362m, 1317m, 1279m, 1171s, 1106s, 1076s, 1036m, 1028m, 996m, 928w, 914w, 876w, 844w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 7.46–7.40 (m, 2 arom. H); 7.39–7.25 (m, 13 arom. H); 4.81 (s, irradi. at 4.24 → NOE of 9%, H–C(8)); 4.67, 4.66 (2d, J = 12.0, 2 PhCH); 4.54 (d, J = 12.0, 2 PhCH); 4.24 (dd, J = 2.1, 0.6, irradi. at 4.81 → NOE of 14%, H–C(6)); 3.77 (br. s, irradi. at 4.24 → NOE of 7%, H–C(5)). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 137.14, 137.06 (2s); 131.37 (2d); 128.49 (2d); 128.44 (2d); 128.07 (2d); 128.04 (d); 128.00 (2d); 127.92 (d); 127.89 (2d); 127.73 (d); 123.70 (s); 71.04, 70.51 (2t, 2 PhCH<sub>2</sub>). MALDI-MS: 491 ([M + Na]<sup>+</sup>). HR-MALDI-MS: 491.1834 ([M + Na]<sup>+</sup>, C<sub>30</sub>H<sub>28</sub>NaO<sub>5</sub><sup>+</sup>; calc. 491.1829). Anal. calc. for C<sub>30</sub>H<sub>28</sub>O<sub>5</sub> (468.55): C 76.90, H 6.02; found: C 76.66, H 6.22.

(Z)-1-O-Acetyl-2,6:3,7-dianhydro-4,5-di-O-benzyl-8,9,10-trideoxy-10-C-phenyl-L-glycero-L-galacto-dec-7-en-9-ynitol (**54**). A suspension of **53** (47 mg, 0.1 mmol) in pyridine (3 ml) was treated with Ac<sub>2</sub>O (66 μl, 0.16 mmol) and stirred overnight at 25°. Co-evaporation three times with toluene and FC (cyclohexane/AcOEt 4:1) gave **54** (49 mg, 95%). R<sub>f</sub> (cyclohexane/AcOEt 2:1) 0.58. IR (CHCl<sub>3</sub>): 3107w, 3090w, 3067w, 3029m, 3014m, 2928s, 2852m, 2260w, 1952w, 1731s, 1664m, 1603w, 1496w, 1453m, 1374m, 1250s, 1146m, 1102s, 1043s, 993m, 909w, 885w, 860w, 821w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 7.46–7.41 (m, 2 arom. H); 7.39–7.25 (m, 13 arom. H); 4.83 (s, H–C(8)); 4.66, 4.65 (2d, J = 12.0, 2 PhCH); 4.55, 4.53 (2d, J = 12.0, 2 PhCH); 2.10 (s, AcO). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): see Table 7; additionally, 170.48 (s, C=O); 137.06, 136.97 (2s); 131.33 (2d); 128.45 (2d); 128.40 (2d); 128.02 (3d); 127.95 (2d); 127.89 (d); 127.85 (2d); 127.68 (d); 123.67 (s); 71.00, 70.52 (2t, 2 PhCH<sub>2</sub>); 20.93 (q, Me).

1,6-Anhydro-4-deoxy-4-C-(4-phenylbuta-1,3-dien-1-yl)-β-D-glucofuranose (**56**). A suspension of [Pd<sub>2</sub>(dba)<sub>3</sub>] (6 mg, 0.0125 mmol), CuI (2 mg, 0.01 mmol), P(fur)<sub>3</sub> (6 mg, 0.0125 mmol), **55** [66] (85 mg, 0.5 mmol), and (bromoethynyl)benzene (91 mg, 0.5 mmol) in DMF (3 ml) was degassed twice and stirred at 22° for 5 min. The mixture was treated with Et<sub>3</sub>N (0.3 ml) and stirred for 12 h at 22°. The soln. was diluted with Et<sub>2</sub>O (10 ml), and treated with H<sub>2</sub>O (10 ml) and 0.1M aq. HCl (3 ml). The Et<sub>2</sub>O layer was washed with H<sub>2</sub>O (2 × 15 ml), and the aq. layer was extracted with Et<sub>2</sub>O (4 × 10 ml). The combined org. fractions were dried (MgSO<sub>4</sub>) and evaporated. FC (cyclohexane/AcOEt 1:1) gave **56** (102 mg, 76%). White solid. R<sub>f</sub> (cyclohexane/AcOEt 1:1) 0.43. M.p. 128–129°. [α]<sub>D</sub><sup>25</sup> = -41.5 (c = 1.02, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3561m, 3385w (br.), 3028w, 3014w, 2960w, 2928w, 2906w, 2855w, 2246w, 2148w, 1730w, 1597w, 1491w, 1442w, 1347w, 1297w, 1264w, 1180w, 1135m, 1111w, 1049s, 1013m, 987m, 928m, 886m, 849w, 814w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 7.52–7.47 (m, 2 arom. H); 7.37–7.29 (m, 3 arom. H); 5.56 (br. s, H–C(1)); 4.69 (br. d, J = 4.8, H–C(5)); 4.22 (d, J = 7.8, H<sub>endo</sub>-C(6)); 4.07 (dq<sub>int.</sub>, J = 7.8, 1.5, addition of D<sub>2</sub>O → q<sub>int.</sub>, J = 1.5, H–C(3)); 3.83 (dd, J = 7.8, 5.1, H<sub>exo</sub>-C(6)); 3.61 (br. d, J = 11.6, addn. of D<sub>2</sub>O → br. s, H–C(2)); 2.94 (br. s, H–C(4)); 2.72 (d, J = 7.8, exchanged with D<sub>2</sub>O, HO–C(3)); 2.43 (d, J = 11.9, exchanged with D<sub>2</sub>O, HO–C(2)). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 132.51 (2d); 129.26 (d); 128.36 (2d); 121.27 (s); 102.22 (d, C(1)); 80.59 (s, C(1')); 77.33 (s, C(4)); 75.07 (d, C(5)); 73.33 (s, C(3')); 72.47 (d, C(3)); 70.47 (d, C(2)); 68.82 (s, C(2')); 67.38 (t, C(6)); 37.20 (d, C(4)). HR-MALDI-MS: 293.0787 ([M + Na]<sup>+</sup>, C<sub>16</sub>H<sub>14</sub>NaO<sub>4</sub>; calc. 293.0784). Anal. calc. for C<sub>16</sub>H<sub>14</sub>O<sub>4</sub>·0.5 H<sub>2</sub>O (279.28): C 68.74, H 5.37; found: C 68.48, H 5.87.

1,6-Anhydro-4-C-(2-bromoethynyl)-4-deoxy-β-D-glucofuranose (**57**). A suspension of **55** (85 mg, 0.5 mmol) and NBS (120 mg, 0.67 mmol) in acetone (5 ml) was treated with AgNO<sub>3</sub> (12 mg, 0.072 mmol) and stirred for 30 min at 22°. After evaporation, the residue was partitioned between H<sub>2</sub>O and AcOEt. The aq. layer was extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/AcOEt 1:1) gave **57** (115 mg, 92%). White solid. R<sub>f</sub> (hexane/AcOEt 1:1) 0.56. M.p. 145–146°. [α]<sub>D</sub><sup>25</sup> = -75.5 (c = 1.01, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3562m, 3393w (br.), 3027w, 3014w, 2961w, 2906w, 2215w, 1602w, 1476w, 1399w, 1348w, 1300w, 1182w, 1134m, 1064s, 1048s, 1008m, 986m, 929w, 884w, 851w, 817w. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 5.53 (br. s, H–C(1)); 4.63 (br. d, J = 5.0, H–C(5)); 4.18 (d, J = 7.8, H<sub>endo</sub>-C(6)); 4.00 (dq<sub>int.</sub>, J = 7.8, 1.5, addition of D<sub>2</sub>O → q<sub>int.</sub>, J = 1.5, H–C(3)); 3.80 (dd, J = 7.5, 5.1, H<sub>exo</sub>-C(6)); 3.57 (br. d, J = 11.5, addition of D<sub>2</sub>O → br. s, H–C(2)); 2.80 (br. s, H–C(4)); 2.67 (d, J = 7.7, exchanged with D<sub>2</sub>O, HO–C(3)); 2.37 (d, J = 11.8, exchanged with D<sub>2</sub>O, HO–C(2)). <sup>13</sup>C-NMR (75 MHz,

CDCl<sub>3</sub>): 102.12 (*d*, C(1)); 78.00 (*s*, C(1')); 75.02 (*d*, C(5)); 72.20 (*d*, C(3)); 70.41 (*d*, C(2)); 67.26 (*t*, C(6)); 43.46 (*s*, C(2')); 37.29 (*d*, C(4)). HR-MALDI-MS: 272.9557 (97, [M + Na]<sup>+</sup>, C<sub>8</sub>H<sub>9</sub><sup>81</sup>BrNaO<sub>4</sub><sup>+</sup>; calc. 272.9561), 270.9578 (100, [M + Na]<sup>+</sup>, C<sub>8</sub>H<sub>9</sub><sup>79</sup>BrNaO<sub>4</sub><sup>+</sup>; calc. 270.9576). Anal. calc. for C<sub>8</sub>H<sub>9</sub>BrO<sub>4</sub> (249.06): C 38.58, H 3.64; found: C 38.64, H 3.86.

*X-Ray Analysis of 57*<sup>6</sup>). Recrystallisation of **57** in Et<sub>2</sub>O/hexane 4:1 gave crystals suitable for X-ray analysis: C<sub>8</sub>H<sub>9</sub>BrO<sub>4</sub> (249.065); monoclinic *P*2<sub>1</sub>; *a* = 7.3149(3), *b* = 6.8396(3), *c* = 8.9967(3) Å, β = 101.902(2)°. *V* = 440.44(3) Å<sup>3</sup>; *Z* = 2; *D*<sub>calc.</sub> = 1.878 Mg/m<sup>3</sup>. Intensities were measured on an *Enraf-Nonius CAD-4* diffractometer with MoK<sub>α</sub> radiation (graphite monochromator, λ = 0.71073 Å) at 298 K, θ range 0.998–27.485°. Of the 1883 total collected reflections, 1877 independent reflections were observed. *R* = 0.0282, *R*<sub>w</sub> = 0.0862.

*1,6-Anhydro-4-deoxy-4-C-(2-iodoethyl)-β-D-glucopyranose (58)*. A soln. of AgNO<sub>3</sub> (65 mg, 0.38 mmol) and dil. NH<sub>3</sub>/H<sub>2</sub>O (one drop) in H<sub>2</sub>O (3 ml) was treated dropwise with a suspension of **55** (43 mg, 0.25 mmol) in acetone (3 ml), stirred for 5 min, treated with NIS (90 mg, 0.4 mmol), and stirred for 30 min at 22° (the mixture became clear after 5 min and then turbid again). After evaporation, the residue was partitioned between H<sub>2</sub>O and AcOEt. The aq. layer was extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 2:1) gave **58** (64 mg, 87%). White solid. *R*<sub>f</sub> (cyclohexane/AcOEt 2:1) 0.43. M.p. 75–76°. [α]<sub>D</sub><sup>25</sup> = –60.1 (*c* = 1.02, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3560*m*, 3401*w* (br.), 3027*w*, 3014*w*, 2967*w*, 2906*w*, 2253*w*, 1602*w*, 1475*w*, 1397*w*, 1348*w*, 1321*w*, 1299*w*, 1227*w*, 1182*w*, 1134*m*, 1080*w*, 1052*m*, 1046*s*, 1007*m*, 986*w*, 909*s*, 884*w*, 850*w*, 817*w*. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 5.50 (br. *s*, H–C(1)); 4.62 (br. *d*, *J* = 5.0, H–C(5)); 4.15 (*d*, *J* = 7.5, H<sub>endo</sub>–C(6)); 4.00 (br. *d*, *J* = 6.9, addition of D<sub>2</sub>O → br. *s*, H–C(3)); 3.77 (*dd*, *J* = 7.5, 5.0, H<sub>exo</sub>–C(6)); 3.55 (br. *d*, *J* = 11.2, addition of D<sub>2</sub>O → br. *s*, H–C(2)); 2.98 (*d*, *J* = 6.9, exchanged with D<sub>2</sub>O, HO–C(3)); 2.89 (br. *d*, *J* = 1.9, H–C(4)); 2.56 (*d*, *J* = 11.5, exchanged with D<sub>2</sub>O, HO–C(2)). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 102.13 (*d*, C(1)); 92.08 (*s*, C(1')); 75.22 (*d*, C(5)); 72.41 (*d*, C(3)); 70.52 (*d*, C(2)); 67.28 (*t*, C(6)); 38.34 (*d*, C(4)); 31.07 (*s*, C(2')). HR-ESI-MS: 318.9423 (100, [M + Na]<sup>+</sup>, C<sub>8</sub>H<sub>9</sub>IO<sub>4</sub><sup>+</sup>; calc. 318.9443). Anal. calc. for C<sub>8</sub>H<sub>9</sub>IO<sub>4</sub> (296.06): C 32.46, H 3.06; found: C 32.35, H 3.15.

*1,6-Anhydro-4-deoxy-4-C-(4-phenylbuta-1,3-dien-1-yl)-β-D-erythro-hex-3-enopyranose (59)*. A suspension of **56** (27 mg, 0.1 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol) and kept at reflux for 10 h. After evaporation, the residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml) and extracted with AcOEt (3 × 15 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/AcOEt 4:1) gave **59** (21 mg, 82%). *R*<sub>f</sub> (hexane/AcOEt 2:1) 0.46. [α]<sub>D</sub><sup>25</sup> = –7.6 (*c* = 1.0, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3579*w*, 3386*w* (br.), 3028*w*, 2988*w*, 2928*s*, 2852*s*, 2209*w*, 1680*w*, 1598*w*, 1491*w*, 1450*m*, 1375*m*, 1360*w*, 1249*s*, 1130*m*, 1045*m*, 930*w*, 904*w*, 872*w*. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 7.53–7.48 (*m*, 2 arom. H); 7.40–7.29 (*m*, 3 arom. H); 6.23 (*dd*, *J* = 4.4, 1.9, H–C(3)); 5.54 (*t*, *J* = 1.6, H–C(1)); 4.75 (*d*, *J* = 3.7, H–C(5)); 3.81 (*d*, *J* = 6.9, H<sub>endo</sub>–C(6)); 3.75 (*dd*, *J* = 6.9, 4.0, H<sub>exo</sub>–C(6)); 3.74 (*ddd*, *J* = 11.0, 4.5, 1.5, addition of D<sub>2</sub>O: *dd*, *J* = 4.5, 1.5, H–C(2)); 1.86 (*d*, *J* = 11.2, exchanged with D<sub>2</sub>O, HO–C(2)). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 133.50 (*d*, C(3)); 132.42 (*2d*); 129.50 (*d*); 128.39 (*2d*); 125.36 (*s*, C(4)); 121.09 (*s*); 101.96 (*d*, C(1)); 83.55 (*s*, C(4')); 78.27 (*s*, C≡C); 73.57 (*d*, C(5)); 73.09 (*s*, C≡C); 69.11 (*t*, C(6)); 65.50 (*d*, C(2)); *s* of C≡C hidden by signals of CDCl<sub>3</sub>. HR-MALDI-MS: 275.0677 ([M + Na]<sup>+</sup>, C<sub>16</sub>H<sub>12</sub>NaO<sub>3</sub><sup>+</sup>; calc. 275.0679). Anal. calc. for C<sub>16</sub>H<sub>12</sub>O<sub>3</sub> (252.27): C 76.18, H 4.79; found: C 76.11, H 4.87.

*X-Ray Analysis of 59*<sup>6</sup>). Recrystallisation of **59** in Et<sub>2</sub>O/hexane 4:1 gave crystals suitable for X-ray analysis: C<sub>16</sub>H<sub>12</sub>O<sub>3</sub> (252.269); orthorhombic *P*2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>; *a* = 7.1054(2), *b* = 9.4375(3), *c* = 19.4351(7) Å. *V* = 1303.26 Å<sup>3</sup>; *Z* = 4; *D*<sub>calc.</sub> = 1.286 Mg/m<sup>3</sup>. Intensities were measured on an *Enraf-Nonius CAD-4* diffractometer with MoK<sub>α</sub> radiation (graphite monochromator, λ = 0.71073 Å) at 298 K, θ range 0.998–27.485°. Of the 2937 total collected reflections, 2920 independent reflections were observed. *R* = 0.0444, *R*<sub>w</sub> = 0.1298.

*1,6-Anhydro-4-C-(2-bromoethenylidene)-4-deoxy-β-D-glucopyranose (60)*. A suspension of **57** (50 mg, 0.2 mmol) in dry MeOH (3 ml) was treated with one batch of MeONa (20 mg, 0.37 mmol) and kept at reflux for 10 h. After evaporation, the residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml) and extracted with AcOEt (3 × 10 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (hexane/AcOEt 4:1) gave **60** (43 mg, 82%). *R*<sub>f</sub> (hexane/AcOEt 2:1) 0.48. [α]<sub>D</sub><sup>25</sup> = –47.7 (*c* = 1.02, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3564*m*, 3401*w* (br.), 3027*m*, 3015*m*, 2968*w*, 2902*w*, 1964*w*, 1730*w*, 1602*w*, 1475*w*, 1394*w*, 1347*w*, 1300*w*, 1123*s*, 1048*s*, 1009*m*, 976*m*, 946*w*, 930*m*, 909*s*, 890*m*, 849*w*, 818*w*. IR (KBr): 3432*s* (br.), 3051*m*, 2963*m*, 2926*m*, 2903*m*, 1964*w*, 1631*w* (br.), 1471*w*, 1432*m*, 1397*m*, 1361*w*, 1345*m*, 1309*m*, 1285*m*, 1266*m*, 1212*w*, 1150*s*, 1128*s*, 1064*s*, 1029*s*, 982*m*, 947*s*, 926*s*, 892*s*, 854*s*. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 9:1 mixture of diastereoisomers: signals of the minor diastereoisomer: 6.27 (*d*, *J* = 1.2, H–C(2')); 5.51 (br. *s*, H–C(1)); 5.02 (*d*, *J* = 4.7, H–C(5)); 4.30 (br. *d*, *J* ≈ 7.0, addition of D<sub>2</sub>O → br. *s*, H–C(3)); 4.20 (*d*, *J* = 7.2, H<sub>endo</sub>–C(6)); 3.87 (*dd*, *J* = 7.4, 4.7, H<sub>exo</sub>–C(6)); 3.70 (br. *dq*, *J* ≈ 8.4, 1.5, addition of D<sub>2</sub>O → br. *s*, H–C(2)); 2.37 (*d*, *J* = 6.8, exchanged

with D<sub>2</sub>O, HO–C(3)); 2.20 (*d*, *J* = 8.7, exchanged with D<sub>2</sub>O, HO–C(2)); signals of the minor diastereoisomer: 6.24 (*br. s*, H–C(2')); 5.05 (*d*, *J* = 4.7, H–C(5)); 4.12 (*d*, *J* = 7.2, H<sub>endo</sub>–C(6)); 2.43 (*d*, *J* = 6.8, exchanged with D<sub>2</sub>O, HO–C(3)); 2.26 (*d*, *J* = 8.7, exchanged with D<sub>2</sub>O, HO–C(2)). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>; 9:1 mixture of diastereoisomers): signals of the major diastereoisomer: 198.59 (*s*, C(1')); 108.58 (*s*, C(4)); 102.55 (*d*, C(1)); 75.49 (*d*, C(5)); 73.50 (*d*, C(3)); 73.08 (*d*, C(2')); 70.88 (*t*, C(6)); 69.40 (*d*, C(2)); signals of the minor diastereoisomer: 73.2 (*d*, C(2')); 69.5 (*d*, C(2)). HR-MALDI-MS: 272.9555 (97, [M + Na]<sup>+</sup>, C<sub>8</sub>H<sub>9</sub><sup>81</sup>BrNaO<sub>4</sub><sup>+</sup>; calc. 272.9561), 270.9577 (100, [M + Na]<sup>+</sup>, C<sub>8</sub>H<sub>9</sub><sup>79</sup>BrNaO<sub>4</sub><sup>+</sup>; calc. 270.9576).

*1,6-Anhydro-4-deoxy-4-C-(2-iodoethenylidene)-β-D-glucopyranose (61)*. A suspension of **58** (50 mg, 0.2 mmol) in dry MeOH (3 ml) was treated with one batch of *t*-BuOK (41 mg, 0.37 mmol) and kept at reflux for 10 h. After evaporation, the residue was treated with a soln. of 0.1M HCl (0.5 ml) in H<sub>2</sub>O (10 ml) and extracted with AcOEt (3 × 10 ml). The combined org. fractions were washed with brine (10 ml), dried (MgSO<sub>4</sub>), and evaporated. FC (cyclohexane/AcOEt 4:1) gave **61** (12 mg, 68%). *R*<sub>f</sub> (hexane/AcOEt 2:1) 0.49. [α]<sub>D</sub><sup>25</sup> = –54.2 (*c* = 1.05, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 3563*m*, 3405*m* (*br.*), 3027*m*, 3015*m*, 2963*m*, 2929*m*, 2901*m*, 2852*w*, 1955*w*, 1602*w*, 1474*w*, 1392*m*, 1345*m*, 1300*w*, 1127*s*, 1056*s*, 1000*m*, 975*m*, 945*m*, 930*m*, 890*m*, 848*m*. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>; 1:1 mixture of diastereoisomers): 6.07, 6.05 (*2t*, *J* = 0.8, H–C(2')); 5.50 (*br. s*, H–C(1)); 5.04, 5.02 (*2 br. d*, *J* = 4.5, H–C(5)); 4.35–4.28 (*br. s*, H–C(3)); 4.18, 4.13 (*2d*, *J* = 7.5, H<sub>endo</sub>–C(6)); 3.86, 3.83 (*2dd*, *J* = 7.5, 4.5, H<sub>exo</sub>–C(6)); 3.69 (*br. d*, *J* = 8.0, H–C(2)); 2.48, 2.41 (*2d*, *J* = 7.1, HO–C(3)); 2.27, 2.23 (*2d*, *J* = 8.2, HO–C(2)). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>; 1:1 mixture of diastereoisomers): 201.03 (*s*, C(1')); 102.65, 102.58 (*2d*, C(1)); 102.09 (*s*, C(4)); 75.16, 73.36 (*2d*, C(5)); 72.66, 72.33 (*2d*, C(3)); 70.30, 70.08 (*2t*, C(6)); 69.62, 68.87 (*2d*, C(2)); 38.97, 38.29 (*2d*, C(2')). HR-ESI-MS: 318.9443 (100, [M + Na]<sup>+</sup>, C<sub>8</sub>H<sub>9</sub>INaO<sub>4</sub><sup>+</sup>; calc. 318.9443).

## REFERENCES

- [1] H. C. Lin, W. B. Yang, Y. F. Gu, C. Y. Chen, C. Y. Wu, C. H. Lin, *Org. Lett.* **2003**, *5*, 1087.
- [2] C. F. Chang, W. B. Yang, C. C. Chang, C. H. Lin, *Tetrahedron Lett.* **2002**, *43*, 6515.
- [3] P. A. Colinas, A. Lieberknecht, R. D. Bravo, *Tetrahedron Lett.* **2002**, *43*, 9065.
- [4] C. Taillefumier, Y. Chapleur, *Chem. Rev.* **2004**, *104*, 263.
- [5] M. Gascón-López, M. Motevalli, G. Paloumbis, P. Bladon, P. B. Wyatt, *Tetrahedron* **2003**, *59*, 9349.
- [6] P. Molas, I. Matheu, S. Castillon, *Tetrahedron Lett.* **2004**, *45*, 3721.
- [7] A. M. Gómez, A. Pedregosa, A. Barrio, S. Valverde, J. C. López, *Tetrahedron Lett.* **2004**, *45*, 6307.
- [8] C. Taillefumier, S. Thielges, Y. Chapleur, *Tetrahedron* **2004**, *60*, 2213.
- [9] E. R. H. Jones, J. S. Stephenson, *J. Chem. Soc.* **1959**, 2197; E. R. H. Jones, J. S. Stephenson, W. B. Turner, M. C. Whiting, *J. Chem. Soc.* **1963**, 2048; R. C. Cambie, A. Hirschberg, E. R. H. Jones, G. Lowe, *J. Chem. Soc.* **1963**, 4120; E. R. H. Jones, G. Lowe, P. V. R. Shannon, *J. Chem. Soc. C* **1966**, 139.
- [10] F. Bohlmann, P. Herbst, H. Gleinig, *Chem. Ber.* **1961**, *94*, 948.
- [11] D. Grandjean, P. Pale, J. Chucho, *Tetrahedron Lett.* **1992**, *33*, 4905; D. Grandjean, P. Pale, J. Chucho, *Tetrahedron Lett.* **1992**, *33*, 5355; J. Chucho, D. Grandjean, P. Pale, *Bull. Soc. Chim. Belg.* **1992**, *101*, 415.
- [12] M. Yoshimatsu, M. Naito, H. Shimizu, O. Muraoka, G. Tanabe, T. Kataoka, *J. Org. Chem.* **1996**, *61*, 8200.
- [13] P. Timmerman, L. E. Witschel, F. Diederich, C. Boudon, J. P. Gisselbrecht, M. Gross, *Helv. Chim. Acta* **1996**, *79*, 6.
- [14] V. Dalla, P. Pale, *New J. Chem.* **1999**, *23*, 803; P. Pale, J. Chucho, *Eur. J. Org. Chem.* **2000**, 1019.
- [15] F. E. McDonald, C. B. Connolly, M. M. Gleason, T. B. Towne, K. D. Treiber, *J. Org. Chem.* **1993**, *58*, 6952; F. E. McDonald, C. C. Schultz, *J. Am. Chem. Soc.* **1994**, *116*, 9363; F. E. McDonald, M. M. Gleason, *J. Am. Chem. Soc.* **1996**, *118*, 6648.
- [16] B. M. Trost, Y. H. Rhee, *J. Am. Chem. Soc.* **2002**, *124*, 2528.
- [17] B. M. Trost, Y. H. Rhee, *J. Am. Chem. Soc.* **2003**, *125*, 7482; B. M. Trost, Y. H. Rhee, *Org. Lett.* **2004**, *6*, 4311.
- [18] P. Wipf, T. H. Graham, *J. Org. Chem.* **2003**, *68*, 8798.
- [19] F. E. McDonald, K. S. Reddy, Y. Diaz, *J. Am. Chem. Soc.* **2000**, *122*, 4304; F. E. McDonald, K. S. Reddy, *Angew. Chem., Int. Ed.* **2001**, *40*, 3653; F. E. McDonald, K. S. Reddy, *J. Organomet. Chem.* **2001**, *617–618*, 444; F. E. McDonald, M. L. Wu, *Org. Lett.* **2002**, *4*, 3979; E. Alcázar, J. M. Pletcher, F. E. McDonald, *Org. Lett.* **2004**, *6*, 3877.
- [20] M. D. Weingarten, A. Padwa, *Tetrahedron Lett.* **1995**, *36*, 4717; A. Padwa, K. E. Krumpe, M. D. Weingarten, *J. Org. Chem.* **1995**, *60*, 5595.
- [21] F. J. Reboredo, M. Treus, J. C. Estévez, L. Castedo, R. J. Estévez, *Synlett* **2002**, 999.
- [22] J. Stichler-Bonaparte, B. Bernet, A. Vasella, *Helv. Chim. Acta* **2002**, *85*, 2235.

- [23] T. V. Bohner, O.-S. Becker, A. Vasella, *Helv. Chim. Acta* **1999**, *82*, 198.
- [24] R. Bürli, A. Vasella, *Helv. Chim. Acta* **1997**, *80*, 2215.
- [25] A. Vasella, *Pure Appl. Chem.* **1998**, *70*, 425.
- [26] B. Bernet, A. Vasella, in 'Acetylene Chemistry. Chemistry, Biology, and Material Science', Eds. F. Diederich, P. J. Stang, R. R. Tykwinski, Wiley-VCH, Weinheim, 2004, p. 173–321.
- [27] M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, J. J. P. Stewart, *J. Am. Chem. Soc.* **1985**, *107*, 3902.
- [28] J. J. P. Stewart, *J. Comput. Chem.* **1989**, *10*, 209.
- [29] Semichem, 'AMPAC 6.0', 7128 Summit, Shawnee, KS 66216, 1998.
- [30] B. Hoffmann, D. Zanini, I. Ripoche, R. Bürli, A. Vasella, *Helv. Chim. Acta* **2001**, *84*, 1862.
- [31] B. Hoffmann, B. Bernet, A. Vasella, *Helv. Chim. Acta* **2002**, *85*, 265.
- [32] P. R. Muddasani, E. Bozó, B. Bernet, A. Vasella, *Helv. Chim. Acta* **1994**, *77*, 257.
- [33] B. Bernet, A. Vasella, *Helv. Chim. Acta* **2000**, *83*, 995.
- [34] F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, C. Caufield, M. Lipton, G. Chang, T. Hendrickson, W. C. Still, *J. Comput. Chem.* **1990**, *11*, 440.
- [35] M. D. Banciu, M. D. Stanescu, C. Florea, A. Petride, C. Draghici, E. Cioranescu, *Bull. Soc. Chim. Fr.* **1991**, 919.
- [36] H.-J. Liu, W.-L. Yeh, E. N. C. Browne, *Can. J. Chem.-Rev. Can. Chim.* **1995**, *73*, 1135.
- [37] J. I. Musher, E. J. Corey, *Tetrahedron* **1962**, *18*, 791.
- [38] C. M. Evans, A. J. Kirby, *J. Chem. Soc., Perkin Trans. 2* **1984**, 1269.
- [39] J. M. J. Tronchet, A. P. Bonenfant, F. Perret, A. Gonzalez, J. B. Zumwald, E. M. Martinez, B. Baehler, *Helv. Chim. Acta* **1980**, *63*, 1181.
- [40] J. M. Aurrecochea, B. Lopez, M. Arrate, *J. Org. Chem.* **2000**, *65*, 6493.
- [41] H. Hofmeister, K. Annen, H. Laurent, R. Wiechert, *Angew. Chem., Int. Ed.* **1984**, *23*, 727.
- [42] M. J. Robins, S. F. Wnuk, X. D. Yang, C. S. Yuan, R. T. Borchardt, J. Balzarini, E. De Clercq, *J. Med. Chem.* **1998**, *41*, 3857.
- [43] N. N. Sveshnikov, V. I. Nikulin, *Magn. Reson. Chem.* **1995**, *33*, 755.
- [44] A. Ernst, A. Vasella, *Helv. Chim. Acta* **1996**, *79*, 1279.
- [45] V. M. S. Gil, W. von Philipsborn, *Magn. Reson. Chem.* **1989**, *27*, 409.
- [46] D. Beer, A. Vasella, *Helv. Chim. Acta* **1985**, *68*, 2254.
- [47] S. Fritschi, A. Vasella, *Helv. Chim. Acta* **1991**, *74*, 2024.
- [48] S. E. Mangholz, A. Vasella, *Helv. Chim. Acta* **1995**, *78*, 1020.
- [49] G. Pairaudeau, P. J. Parsons, J. M. Underwood, *J. Chem. Soc., Chem. Commun.* **1987**, 1718.
- [50] S. Takano, Y. Iwabuchi, K. Ogasawara, *J. Chem. Soc., Chem. Commun.* **1989**, 1371.
- [51] C. Mukai, H. Yamashita, M. Hanaoka, *Org. Lett.* **2001**, *3*, 3385.
- [52] V. K. Brel, *Synthesis* **2001**, 1539.
- [53] G. Bendz, *Ark. Kemi* **1959**, *14*, 475; G. Bendz, *Ark. Kemi* **1960**, *15*, 131.
- [54] R. E. Bew, J. R. Chapman, E. R. H. Jones, B. E. Lowe, G. Lowe, *J. Chem. Soc. C* **1966**, 129.
- [55] L. I. Olsson, A. Claesson, *Synthesis* **1979**, 743.
- [56] J. Grimaldi, A. Cormons, *C. R. Hebd. Séances Acad. Sci., Ser. C* **1979**, *289*, 373.
- [57] J.-J. Chilot, A. Doutheau, J. Gore, *Tetrahedron Lett.* **1982**, *23*, 4693; J.-J. Chilot, A. Doutheau, J. Gore, *Bull. Soc. Chim. Fr., Part. II* **1984**, 307.
- [58] A. Jellal, J. Grimaldi, M. Santelli, *Tetrahedron Lett.* **1984**, *25*, 3179.
- [59] H. Ohno, H. Hamaguchi, M. Ohata, T. Tanaka, *Angew. Chem., Int. Ed.* **2003**, *42*, 1749.
- [60] V. G. Andreev, A. F. Kolomiets, A. V. Fokin, *Bull. Acad. Sci. USSR, Div. Chem. Sci.* **1991**, *40*, 2447.
- [61] R. Paul, S. Tchelitcheff, *Compt. Rend.* **1950**, *230*, 1872.
- [62] G. Eglinton, E. R. H. Jones, M. C. Whiting, *J. Chem. Soc.* **1952**, 2873.
- [63] V. A. Olah, A. Liptak, J. Harangi, P. Nanasi, *Acta Chim. Hung.* **1985**, *118*, 25.
- [64] W. Yuan, S. A. Babirad, Y. Kishi, *J. Org. Chem.* **1992**, *57*, 468.
- [65] E. A. Larsson, J. Ulicny, A. Laaksonen, G. Widmalm, *Org. Lett.* **2002**, *4*, 1831.
- [66] J. Alzeer, C. Cai, A. Vasella, *Helv. Chim. Acta* **1995**, *78*, 242.
- [67] P. Uhlmann, A. Vasella, *Helv. Chim. Acta* **1992**, *75*, 1979.
- [68] M. Brossi, C. Ganter, *Helv. Chim. Acta* **1988**, *71*, 848; M. Brossi, C. Ganter, *Helv. Chim. Acta* **1987**, *70*, 1963.
- [69] H. Westmijze, H. Kleijn, H. J. T. Bos, P. Vermeer, *J. Organomet. Chem.* **1980**, *199*, 293.

Received March 8, 2005